Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Nuclear Medicine

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 460 articles: HTML format

Single Articles

June 2025
1. MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
   The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country.
   J Nucl Med. 2025 Jun 12:jnumed.125.269996. doi: 10.2967/jnumed.125.269996.
   PubMed     Abstract available
   
   
   
2. BOBBA KN, Wadhwa A, Bidkar AP, Raveendran A, et al
   Evaluation of (134)Ce/(134)La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer.
   J Nucl Med. 2025 Jun 12:jnumed.125.269751. doi: 10.2967/jnumed.125.269751.
   PubMed     Abstract available
   
   
   
3. YUE J, Zhang Y, Miu Y, Zhao Y, et al
   Radiopharmaceutical Therapy: Balancing Absorbed Dose and Antitumor Immunity.
   J Nucl Med. 2025 Jun 12:jnumed.125.269868. doi: 10.2967/jnumed.125.269868.
   PubMed    
   
   
   
4. KWON D, Li EJ, Dulal C, Daube-Witherspoon M, et al
   Dual-Tracer Imaging on a Long-Axial-Field-of-View PET: A Proof-of-Principle Study with [(18)F]FGln and [(18)F]FDG.
   J Nucl Med. 2025 Jun 12:jnumed.124.268831. doi: 10.2967/jnumed.124.268831.
   PubMed     Abstract available
   
   
   
5. DRZEZGA A, Barthel H
   Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition.
   J Nucl Med. 2025;66.
   PubMed     Abstract available
   
   
   
6. FANTI S, Robles Barba JJ, Behr S, Maurer T, et al
   Imaging Efficacy of [(18)F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.
   J Nucl Med. 2025 Jun 5:jnumed.124.269266. doi: 10.2967/jnumed.124.269266.
   PubMed     Abstract available
   
   
   
7. IAGARU A, Suarez JF, Behr S, Aggarwal R, et al
   Imaging Efficacy of [(18)F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.
   J Nucl Med. 2025 Jun 5:jnumed.124.269007. doi: 10.2967/jnumed.124.269007.
   PubMed     Abstract available
   
   
   
8. GAFITA A, Schroeder JA, Ceci F, Oldan JD, et al
   Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT.
   J Nucl Med. 2025 Jun 5:jnumed.124.268071. doi: 10.2967/jnumed.124.268071.
   PubMed     Abstract available
   
   
   
9. MANSUR A, McConathy JE, Stringer-Reasor E, Rocque G, et al
   Quantitative [(89)Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI.
   J Nucl Med. 2025 Jun 5:jnumed.124.268931. doi: 10.2967/jnumed.124.268931.
   PubMed     Abstract available
   
   
   
10. COOLS R, Vermeulen K, Vonck E, Baekelandt V, et al
    In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [(11)C]HSP990 in Healthy Aging and Neurodegeneration.
    J Nucl Med. 2025;66:940-947.
    PubMed     Abstract available
    
    
    
11. KAYAL G, Roseland ME, Wang C, Fitzpatrick K, et al
    Multicycle Dosimetric Behavior and Dose-Effect Relationships in [(177)Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
    J Nucl Med. 2025;66:900-908.
    PubMed     Abstract available
    
    
    May 2025
12. PALARD-NOVELLO X, Visser D, Yaqub M, van de Giessen E, et al
    Whole-Body [(18)F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View.
    J Nucl Med. 2025 May 29:jnumed.124.268979. doi: 10.2967/jnumed.124.268979.
    PubMed     Abstract available
    
    
    
13. LYNCH SE, Crawford C, Hunt AL, Sligh LL, et al
    Granzyme B PET Imaging Predicts Response to Immunotherapy in a Diet-Induced Obesity Model of Breast Cancer.
    J Nucl Med. 2025 May 29:jnumed.124.268938. doi: 10.2967/jnumed.124.268938.
    PubMed     Abstract available
    
    
    
14. LILBURN DML, Garthwaite HS, Ganeshan B, Win T, et al
    [(18)F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
    J Nucl Med. 2025 May 29:jnumed.125.269497. doi: 10.2967/jnumed.125.269497.
    PubMed     Abstract available
    
    
    
15. AKHAVANALLAF A, Lu Z, Peterson AB, Blakkisrud J, et al
    Can (177)Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data.
    J Nucl Med. 2025 May 22:jnumed.124.269098. doi: 10.2967/jnumed.124.269098.
    PubMed     Abstract available
    
    
    
16. TRAUTWEIN NF, Mattern S, Hinterleitner M, Reischl G, et al
    Histologic Ex Vivo Validation of the [(18)F]SITATE Somatostatin Receptor PET Tracer.
    J Nucl Med. 2025 May 22:jnumed.125.269619. doi: 10.2967/jnumed.125.269619.
    PubMed     Abstract available
    
    
    
17. RAMOS CD
    Redefining Nuclear Medicine: "Biodistribution" Should Be the Core Concept.
    J Nucl Med. 2025 May 22:jnumed.125.270245. doi: 10.2967/jnumed.125.270245.
    PubMed    
    
    
    
18. MOSTAFAPOUR S, van Sluis J, Lammertsma AA, Tsoumpas C, et al
    Reply to "(176)Lu Radiation in Long-Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety".
    J Nucl Med. 2025 May 15:jnumed.125.270027. doi: 10.2967/jnumed.125.270027.
    PubMed    
    
    
    
19. ZHANG W, Yao W, Shen G
    [(68)Ga]Ga-FAPI PET/CT Monitors Response to Receptor Activator of Nuclear Factor-kappaB Ligand Inhibitor in a Giant Cell Tumor of Bone: Correlation with Histopathology.
    J Nucl Med. 2025 May 15:jnumed.124.269432. doi: 10.2967/jnumed.124.269432.
    PubMed    
    
    
    
20. CARTER LM, Milman R, Ocampo Ramos JC, Kesner AL, et al
    (176)Lu Radiation in Long-Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety.
    J Nucl Med. 2025 May 15:jnumed.125.269846. doi: 10.2967/jnumed.125.269846.
    PubMed    
    
    
    
21. BAILEY DL, Meikle SR, Calamante F, Angelis G, et al
    The Australian National Total-Body PET Facility-A Shared Resource and Risk Model for Implementing Total-Body PET.
    J Nucl Med. 2025 May 15:jnumed.125.269859. doi: 10.2967/jnumed.125.269859.
    PubMed    
    
    
    
22. ZHAO Q, Liow JS, Jee JE, Montero Santamaria J, et al
    [(11)C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey Brain Phosphodiesterase Type 4 Subtype B.
    J Nucl Med. 2025 May 8:jnumed.124.269159. doi: 10.2967/jnumed.124.269159.
    PubMed     Abstract available
    
    
    
23. YEH R, Pareja F, Shobeiri P, Ross D, et al
    Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis.
    J Nucl Med. 2025 May 8:jnumed.124.269227. doi: 10.2967/jnumed.124.269227.
    PubMed     Abstract available
    
    
    
24. DUBROFF JG, Hsieh CJ, Wiers CE, Lee H, et al
    [(11)C]Carfentanil PET Whole-Body Imaging of mu-Opioid Receptors: A First in-Human Study.
    J Nucl Med. 2025 May 8:jnumed.124.269413. doi: 10.2967/jnumed.124.269413.
    PubMed     Abstract available
    
    
    
25. ICHIJO S, Arisawa T, Hatano M, Nakajima W, et al
    First-in-Human Study of (18)F-Labeled PET Tracer for Glutamate AMPA Receptor [(18)F]K-40: A Derivative of [(11)C]K-2.
    J Nucl Med. 2025 May 8:jnumed.124.269405. doi: 10.2967/jnumed.124.269405.
    PubMed     Abstract available
    
    
    
26. ZARAGORI T, Chevalier E, Citerne Q, Roch V, et al
    Assessment of [(177)Lu]Lu-DOTATATE Dosimetry from High-Speed Whole-Body Recordings Provided by a 360 degrees Cadmium-Zinc-Telluride Camera Compared with Results from a Conventional Anger-Camera Protocol.
    J Nucl Med. 2025;66:771-777.
    PubMed     Abstract available
    
    
    
27. PICHLER V, Schwingenschlogl-Maisetschlager V, Duman I, Monforte X, et al
    Bioanalytic Hybrid System Merging 3-Dimensional Cell Culture and Chromatographic Precision for Unprecedented Preclinical Insights in Molecular Imaging.
    J Nucl Med. 2025;66:813-816.
    PubMed     Abstract available
    
    
    
28. TOURNIER N, Langer O
    Imaging the Activity of Efflux Transporters at the Blood-Brain Barrier in Neurologic Diseases: Radiotracer Selection Criteria.
    J Nucl Med. 2025;66:676-680.
    PubMed     Abstract available
    
    
    April 2025
29. CHUNG KJ, Chaudhari AJ, Nardo L, Jones T, et al
    Quantitative Total-Body Imaging of Blood Flow with High-Temporal-Resolution Early Dynamic (18)F-FDG PET Kinetic Modeling.
    J Nucl Med. 2025 Apr 30:jnumed.124.268706. doi: 10.2967/jnumed.124.268706.
    PubMed     Abstract available
    
    
    
30. FROEHNER M, Zophel K
    (177)Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?
    J Nucl Med. 2025 Apr 30:jnumed.125.269875. doi: 10.2967/jnumed.125.269875.
    PubMed    
    
    
    
31. FELBER V, Holzleitner N, Joksch M, Suhrbier T, et al
    First-in-Human Serum Stability Studies of [(177)Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Apr 30:jnumed.124.269132. doi: 10.2967/jnumed.124.269132.
    PubMed     Abstract available
    
    
    
32. WENZEL M, Groener D, Chun FKH, Mandel P, et al
    Reply to "(177)Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?".
    J Nucl Med. 2025 Apr 30:jnumed.125.270028. doi: 10.2967/jnumed.125.270028.
    PubMed    
    
    
    
33. TRIVIERI MG, Devesa A, Robson PM, Bose S, et al
    Prevalence of Persistent Cardiovascular and Pulmonary Abnormalities on PET/MRI and DECT Imaging in Long COVID Patients.
    J Nucl Med. 2025 Apr 30:jnumed.124.268980. doi: 10.2967/jnumed.124.268980.
    PubMed     Abstract available
    
    
    
34. PARIHAR AS, Pant N, Heidari P, Fong L, et al
    Approaches to Imaging Immune Activation Using PET.
    J Nucl Med. 2025 Apr 30:jnumed.124.268289. doi: 10.2967/jnumed.124.268289.
    PubMed     Abstract available
    
    
    
35. SHI B, Zhang Y, Wu S, Xu D, et al
    CD70-Targeted [(18)F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study.
    J Nucl Med. 2025 Apr 30:jnumed.125.269585. doi: 10.2967/jnumed.125.269585.
    PubMed     Abstract available
    
    
    
36. FRANCA VELO A, Giantini Larsen A, Humm JL, Zanzonico P, et al
    Determination of the Intralesional Distribution of Theranostic (124)I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma.
    J Nucl Med. 2025 Apr 30:jnumed.124.267995. doi: 10.2967/jnumed.124.267995.
    PubMed     Abstract available
    
    
    
37. DERLIN T, Kleine-Dopke D, Neubert L, Ross TL, et al
    Initial Experience with Dual-Time-Point [(18)F]Flurpiridaz PET/CT for Localization of Parathyroid Adenomas in Primary Hyperparathyroidism.
    J Nucl Med. 2025 Apr 24:jnumed.124.269387. doi: 10.2967/jnumed.124.269387.
    PubMed     Abstract available
    
    
    
38. ZIMMERMANN R, Beyer T
    Stakeholders of Theranostics: Thomas Beyer Talks with Richard Zimmermann About the Golden Age of Nuclear Medicine.
    J Nucl Med. 2025 Apr 24:jnumed.125.270085. doi: 10.2967/jnumed.125.270085.
    PubMed    
    
    
    
39. UNTERRAINER LM, De Leiris N, Unterrainer M, Delker A, et al
    Evidence-Based Clinical Protocols to Monitor Efficacy of [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
    J Nucl Med. 2025 Apr 24:jnumed.124.269431. doi: 10.2967/jnumed.124.269431.
    PubMed     Abstract available
    
    
    
40. SMITH CLC, Zwezerijnen GJC, den Hollander ME, Zijlstra JM, et al
    Feasibility of Ultra-Low-Activity (18)F-FDG PET/CT Imaging Using a Long-Axial-Field-of-View PET/CT System.
    J Nucl Med. 2025 Apr 24:jnumed.124.269272. doi: 10.2967/jnumed.124.269272.
    PubMed     Abstract available
    
    
    
41. THACKERAY JT
    2024 SNMMI Highlights Lecture: Cardiovascular Sciences.
    J Nucl Med. 2025 Apr 24:jnumed.125.269988. doi: 10.2967/jnumed.125.269988.
    PubMed     Abstract available
    
    
    
42. DAKANALI M, Zigler SS, Schwarz SW, Nickels ML, et al
    FDA Reconsiders Rules Around Radiation Dosimetry for First-in-Human Studies of Investigational PET Radiopharmaceuticals.
    J Nucl Med. 2025 Apr 17:jnumed.125.269885. doi: 10.2967/jnumed.125.269885.
    PubMed    
    
    
    
43. SCHINDLER TH, Bateman TM, Berman DS, Chareonthaitawee P, et al
    FDA Approval of (18)F-Flurpiridaz Is for PET: Stepping into a New Area of Myocardial Perfusion Imaging?
    J Nucl Med. 2025 Apr 17:jnumed.124.269154. doi: 10.2967/jnumed.124.269154.
    PubMed    
    
    
    
44. ALBERTS I, More S, Knapp K, Mei R, et al
    Is Long-Axial-Field-of-View PET/CT Cost-Effective? An International Health-Economic Analysis.
    J Nucl Med. 2025 Apr 17:jnumed.124.269203. doi: 10.2967/jnumed.124.269203.
    PubMed     Abstract available
    
    
    
45. BRUMBERG J, Schroter N, Blazhenets G, Omrane MA, et al
    [(18)F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies.
    J Nucl Med. 2025 Apr 17:jnumed.124.268956. doi: 10.2967/jnumed.124.268956.
    PubMed     Abstract available
    
    
    
46. FAROLFI A, Casadei B, Malizia C, Ussia R, et al
    Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study.
    J Nucl Med. 2025 Apr 17:jnumed.125.269670. doi: 10.2967/jnumed.125.269670.
    PubMed     Abstract available
    
    
    
47. HACHEY JS, Viray TD, Matasci M, Ravazza D, et al
    Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.
    J Nucl Med. 2025 Apr 17:jnumed.124.268859. doi: 10.2967/jnumed.124.268859.
    PubMed     Abstract available
    
    
    
48. DE OLIVEIRA TAVEIRA M, Razmaria AA, Schoder H, Yeh R, et al
    Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA PET/CT.
    J Nucl Med. 2025 Apr 10:jnumed.124.269361. doi: 10.2967/jnumed.124.269361.
    PubMed     Abstract available
    
    
    
49. SARI H, Teimoorisichani M, Viscione M, Mingels C, et al
    Feasibility of an Ultra-Low-Dose PET Scan Protocol with CT-Based and LSO-TX-Based Attenuation Correction Using a Long-Axial-Field-of-View PET/CT Scanner.
    J Nucl Med. 2025 Apr 10:jnumed.124.268380. doi: 10.2967/jnumed.124.268380.
    PubMed     Abstract available
    
    
    
50. ZHANG Y, Yue J, Yang X, Fei G, et al
    [(68)Ga]Ga-RAYZ-8009: A Peptide PET Tracer for Targeting HCC in Humans.
    J Nucl Med. 2025 Apr 10:jnumed.124.269294. doi: 10.2967/jnumed.124.269294.
    PubMed    
    
    
    
51. HICKS RJ
    Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?
    J Nucl Med. 2025 Apr 3:jnumed.125.269496. doi: 10.2967/jnumed.125.269496.
    PubMed    
    
    
    
52. BARRY N, Kendrick J, Rowshanfarzad P, Hassan GM, et al
    An External, Independent Validation of an O-(2-[(18)F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma.
    J Nucl Med. 2025 Apr 3:jnumed.124.268925. doi: 10.2967/jnumed.124.268925.
    PubMed     Abstract available
    
    
    
53. LEE Y, Nguyen TD, Du Y, Coughlin JM, et al
    Validating the Utility of Supervised Clustering Algorithm for Precise [(11)C]DPA-713 PET Brain Image Quantification.
    J Nucl Med. 2025 Apr 3:jnumed.124.268519. doi: 10.2967/jnumed.124.268519.
    PubMed     Abstract available
    
    
    
54. SCHOLTISSEK H, Reitsam NG, Dierks A, Kroncke T, et al
    Noninvasive Characterization of Hepatic Lesions by Means of Glypican-3-Directed PET/CT.
    J Nucl Med. 2025 Apr 3:jnumed.124.269290. doi: 10.2967/jnumed.124.269290.
    PubMed    
    
    
    
55. GIORGIO J, Soleimani-Meigooni DN, Janabi M, Baker SL, et al
    Imaging Synaptic Density in Aging and Alzheimer Disease with [(18)F]SynVesT-1.
    J Nucl Med. 2025;66:620-625.
    PubMed     Abstract available
    
    
    
56. LI X, Zhang Y, Mixdorf JC, Wu Q, et al
    Development and Preclinical Evaluation of [(64)Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics.
    J Nucl Med. 2025;66:552-558.
    PubMed     Abstract available
    
    
    
57. LI S, Abdelhafez YG, Nardo L, Cherry SR, et al
    Total-Body Parametric Imaging Using Relative Patlak Plot.
    J Nucl Med. 2025;66:654-661.
    PubMed     Abstract available
    
    
    
58. MILLER RJH, Kavanagh P, Lemley M, Liang JX, et al
    Artificial Intelligence-Enhanced Perfusion Scoring Improves the Diagnostic Accuracy of Myocardial Perfusion Imaging.
    J Nucl Med. 2025;66:648-653.
    PubMed     Abstract available
    
    
    
59. UDOVICICH C, Bressel M, Manji J, Ali M, et al
    PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study.
    J Nucl Med. 2025;66:531-536.
    PubMed     Abstract available
    
    
    March 2025
60. AL-IBRAHEEM A, Scott AM, Abdlkadir AS, Vrachimis A, et al
    Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative.
    J Nucl Med. 2025 Mar 27:jnumed.124.269215. doi: 10.2967/jnumed.124.269215.
    PubMed     Abstract available
    
    
    
61. MECKEL M, Ehrenberg S, Schmidt T, Ritt P, et al
    Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium Paraaminohippurate Coadministration in a Rat Model.
    J Nucl Med. 2025 Mar 27:jnumed.124.268411. doi: 10.2967/jnumed.124.268411.
    PubMed     Abstract available
    
    
    
62. SABAHI Z, Nguyen A, Wong K, Li S, et al
    Diagnostic Potential of (68)Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease.
    J Nucl Med. 2025 Mar 27:jnumed.124.268896. doi: 10.2967/jnumed.124.268896.
    PubMed     Abstract available
    
    
    
63. CHEN DC, Buteau JP, Emmett L, Alipour R, et al
    Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [(68)Ga]Ga-PSMA-11 PET/CT in the proPSMA Study.
    J Nucl Med. 2025 Mar 27:jnumed.124.268901. doi: 10.2967/jnumed.124.268901.
    PubMed     Abstract available
    
    
    
64. HERR FL, Dascalescu C, Fabritius MP, Sheikh GT, et al
    PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Mar 27:jnumed.124.268621. doi: 10.2967/jnumed.124.268621.
    PubMed     Abstract available
    
    
    
65. HINDIE E, Patel RB
    Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions.
    J Nucl Med. 2025 Mar 27:jnumed.125.269644. doi: 10.2967/jnumed.125.269644.
    PubMed    
    
    
    
66. SUN H, Cheng D, Du X, Sun C, et al
    A Rare Influenza B Virus-Associated Cerebellitis Detected by (18)F-FDG PET/CT Imaging.
    J Nucl Med. 2025 Mar 27:jnumed.125.269548. doi: 10.2967/jnumed.125.269548.
    PubMed    
    
    
    
67. TANG W, Qi L, Chen M, Zhang Y, et al
    Additive Value of [(68)Ga]Ga-RM26 PET/CT to [(68)Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study.
    J Nucl Med. 2025 Mar 20:jnumed.124.269189. doi: 10.2967/jnumed.124.269189.
    PubMed     Abstract available
    
    
    
68. BOELLAARD R, Zwezerijnen GJC, Buvat I, Champion L, et al
    Measuring Total Metabolic Tumor Volume from (18)F-FDG PET: A Reality Check.
    J Nucl Med. 2025 Mar 13:jnumed.124.269271. doi: 10.2967/jnumed.124.269271.
    PubMed     Abstract available
    
    
    
69. HAUSMANN P, Zschaeck S, Furth C, Nikulin P, et al
    Tumor Asphericity in FDG PET Is an Independent Prognostic Parameter Improving Risk Stratification in Patients with Head and Neck Squamous Cell Carcinoma.
    J Nucl Med. 2025 Mar 13:jnumed.124.268972. doi: 10.2967/jnumed.124.268972.
    PubMed     Abstract available
    
    
    
70. CONSTANTINO CS, Oliveira FPM, Machado M, Vinga S, et al
    The Use of Maximum-Intensity Projections and Deep Learning Adds Value to the Fully Automatic Segmentation of Lesions Avid for [(18)F]FDG and [(68)Ga]Ga-PSMA in PET/CT.
    J Nucl Med. 2025 Mar 13:jnumed.124.269067. doi: 10.2967/jnumed.124.269067.
    PubMed     Abstract available
    
    
    
71. REED MB, Murgas M, Lanzenberger R, Hahn A, et al
    The Value of Functional PET in Quantifying Neurotransmitter Dynamics.
    J Nucl Med. 2025 Mar 13:jnumed.124.269238. doi: 10.2967/jnumed.124.269238.
    PubMed    
    
    
    
72. TUNALI I, Wang J, Arora AK, Kim MJ, et al
    Development and Validation of a (18)F-Flortaucipir PET Visual Stratification Method.
    J Nucl Med. 2025 Mar 13:jnumed.124.268700. doi: 10.2967/jnumed.124.268700.
    PubMed     Abstract available
    
    
    
73. MORRIS ED, Emvalomenos GM, Hoye J, Meikle SR, et al
    Reply to "The Value of Functional PET in Quantifying Neurotransmitter Dynamics".
    J Nucl Med. 2025 Mar 13:jnumed.125.269473. doi: 10.2967/jnumed.125.269473.
    PubMed    
    
    
    
74. PARIHAR AS, Vaz S, Sutcliffe S, Pant N, et al
    (18)F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis.
    J Nucl Med. 2025 Mar 13:jnumed.124.269163. doi: 10.2967/jnumed.124.269163.
    PubMed     Abstract available
    
    
    
75. MORAITIS A, Prochnow A, Poeppel TD, Schmitz J, et al
    Tumor Dose-Response Relationship of [(131)I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [(124)I]MIBG PET.
    J Nucl Med. 2025 Mar 13:jnumed.124.269377. doi: 10.2967/jnumed.124.269377.
    PubMed     Abstract available
    
    
    
76. BERNER K, Hernes E, Kvassheim M, Revheim ME, et al
    First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted (212)Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Mar 13:jnumed.124.269299. doi: 10.2967/jnumed.124.269299.
    PubMed     Abstract available
    
    
    
77. LIU S, Pan Q, Zhang H, Peng L, et al
    Differences in Fibroinflammatory Activity Shown on (68)Ga-FAPI-04 and (18)F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease.
    J Nucl Med. 2025 Mar 6:jnumed.124.268943. doi: 10.2967/jnumed.124.268943.
    PubMed     Abstract available
    
    
    
78. JUWEID ME, Al-Leimon O, Al-Qasem SF, Aljarah I, et al
    Self-Citation Among Highly Cited Nuclear Medicine and Medical Imaging Researchers.
    J Nucl Med. 2025 Mar 6:jnumed.124.269357. doi: 10.2967/jnumed.124.269357.
    PubMed    
    
    
    
79. METSER U, Lukovic J, Mesci A, MacCrostie P, et al
    [(18)F]-FDG PET/CT in the Initial Staging of Squamous Cell Cancer of the Anal Canal: Results of a Prospective Multicenter Registry.
    J Nucl Med. 2025 Mar 6:jnumed.124.269289. doi: 10.2967/jnumed.124.269289.
    PubMed     Abstract available
    
    
    
80. FOXTON C, Waldron B, Veggerby Gronlund R, Simon JJ, et al
    Preclinical Evaluation of (177)Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy.
    J Nucl Med. 2025 Mar 6:jnumed.124.268508. doi: 10.2967/jnumed.124.268508.
    PubMed     Abstract available
    
    
    
81. KNUUTI J, Kobylecka M, Krajewski S, Steczek L, et al
    Biodistribution, Safety Profile, and Radiation Dosimetry of [(18)F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects.
    J Nucl Med. 2025 Mar 6:jnumed.124.268872. doi: 10.2967/jnumed.124.268872.
    PubMed     Abstract available
    
    
    
82. IMBER BS, Yu KKH, Abida W, Pike LRG, et al
    Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2025 Mar 6:jnumed.124.269175. doi: 10.2967/jnumed.124.269175.
    PubMed    
    
    
    
83. WANG R, Wang J, Xiang J, Sui H, et al
    Comparison of [(68)Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [(18)F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Mar 6:jnumed.124.268258. doi: 10.2967/jnumed.124.268258.
    PubMed     Abstract available
    
    
    
84. KURKOWSKA S, Brosch-Lenz J, Dewaraja YK, Frey E, et al
    An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 4: Impact of Fitting Functions in Estimated Absorbed Doses.
    J Nucl Med. 2025;66:441-448.
    PubMed     Abstract available
    
    
    
85. BODEI L, Cremonesi M, Ferrari M, Mittra ES, et al
    Dosimetry of [(177)Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.
    J Nucl Med. 2025;66:449-456.
    PubMed     Abstract available
    
    
    
86. FU JF, Juttukonda MR, Garimella A, Salvatore AN, et al
    [(18)F]MK-6240 Radioligand Delivery Indices as Surrogates of Cerebral Perfusion: Bias and Correlation Against [(15)O]Water.
    J Nucl Med. 2025;66:410-417.
    PubMed     Abstract available
    
    
    
87. AHMAD AA, Ghim M, Kukreja G, Neishabouri A, et al
    Collagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis.
    J Nucl Med. 2025;66:425-433.
    PubMed     Abstract available
    
    
    
88. GILLETT D, Senanayake R, MacFarlane J, Bashari W, et al
    A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[(18)F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism.
    J Nucl Med. 2025;66:434-440.
    PubMed     Abstract available
    
    
    
89. MARQUIS H, Schmidtlein CR, de Nijs R, Minguez Gabina P, et al
    MIRD Pamphlet No. 32: A MIRD Recovery Coefficient Model for Resolution Characterization and Shape-Specific Partial-Volume Correction.
    J Nucl Med. 2025;66:457-465.
    PubMed     Abstract available
    
    
    February 2025
90. MURTHY V, Ludwig V, Gafita A, Hope TA, et al
    The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.268818. doi: 10.2967/jnumed.124.268818.
    PubMed     Abstract available
    
    
    
91. MENCH A, Winters C, Mittra E, Szidonya L, et al
    Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists.
    J Nucl Med. 2025 Feb 27:jnumed.124.268522. doi: 10.2967/jnumed.124.268522.
    PubMed     Abstract available
    
    
    
92. WANG J, Lan X, Shi H, Li S, et al
    A Brief Report on the Results of the 2024 National Survey of Nuclear Medicine Conducted by the Chinese Society of Nuclear Medicine.
    J Nucl Med. 2025 Feb 27:jnumed.124.269044. doi: 10.2967/jnumed.124.269044.
    PubMed    
    
    
    
93. CONSTANZO J, Parach A, David T, Karam J, et al
    MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.268857. doi: 10.2967/jnumed.124.268857.
    PubMed     Abstract available
    
    
    
94. TURCO F, Gillessen S, Herrmann K, Paone G, et al
    Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.267730. doi: 10.2967/jnumed.124.267730.
    PubMed     Abstract available
    
    
    
95. VERA P, Giraud P, Hapdey S, Gouel P, et al
    Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.
    J Nucl Med. 2025 Feb 27:jnumed.124.268499. doi: 10.2967/jnumed.124.268499.
    PubMed     Abstract available
    
    
    
96. GAJECKI L, Lebedeva IV, Liao YR, Ambriz D, et al
    IL13Ralpha2-Targeting Antibodies for Immuno-PET in Solid Malignancies.
    J Nucl Med. 2025 Feb 20:jnumed.124.268762. doi: 10.2967/jnumed.124.268762.
    PubMed     Abstract available
    
    
    
97. CHEVALEYRE C, Zimmermann L, Specklin S, Kereselidze D, et al
    PET Imaging of PD-L1 Occupancy for Preclinical Assessment of the Efficacy of Combined Anti-PD-L1 Immunotherapy and Targeted Therapy.
    J Nucl Med. 2025 Feb 20:jnumed.124.268586. doi: 10.2967/jnumed.124.268586.
    PubMed     Abstract available
    
    
    
98. VIERING O, Holzleitner N, Claus R, Amerein A, et al
    CCK(2) Receptor Ligand [(68)Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [(68)Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer.
    J Nucl Med. 2025 Feb 20:jnumed.124.269201. doi: 10.2967/jnumed.124.269201.
    PubMed    
    
    
    
99. VAN RIJSEWIJK ND, Lanz P, Wouthuyzen-Bakker M, Glaudemans AWJM, et al
    Evaluating Bone Healing with [(18)F]NaF PET/CT During Bone Segment Transport in Femoral Fracture Treatment.
    J Nucl Med. 2025 Feb 20:jnumed.124.268913. doi: 10.2967/jnumed.124.268913.
    PubMed    
    
    
    
100. BABEKER H, Njotu FN, Pougoue Ketchemen J, Monzer A, et al
     (225)Ac/(89)Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer.
     J Nucl Med. 2025 Feb 20:jnumed.124.268387. doi: 10.2967/jnumed.124.268387.
     PubMed     Abstract available
     
     
     
101. SANTORO-FERNANDES V, Schott B, Weisman AJ, Lokre O, et al
     Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy.
     J Nucl Med. 2025 Feb 13:jnumed.124.267809. doi: 10.2967/jnumed.124.267809.
     PubMed     Abstract available
     
     
     
102. MOSTAFAPOUR S, van Sluis J, Lammertsma AA, Tsoumpas C, et al
     (176)Lu Radiation Dose of Long-Axial Field of View PET Scanners.
     J Nucl Med. 2025 Feb 13:jnumed.124.269187. doi: 10.2967/jnumed.124.269187.
     PubMed    
     
     
     
103. YU S, Yang Z, Ding Z, Jia Y, et al
     (68)Ga-FAPI-04 PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in Lupus Nephritis.
     J Nucl Med. 2025 Feb 13:jnumed.124.268643. doi: 10.2967/jnumed.124.268643.
     PubMed     Abstract available
     
     
     
104. SUN Y, Hao Z, Gao H, Yang G, et al
     [(99m)Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study.
     J Nucl Med. 2025 Feb 13:jnumed.124.268564. doi: 10.2967/jnumed.124.268564.
     PubMed     Abstract available
     
     
     
105. YUSUFALY T, Roncali E, Brosch-Lenz J, Uribe C, et al
     Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
     J Nucl Med. 2025 Feb 13:jnumed.124.267927. doi: 10.2967/jnumed.124.267927.
     PubMed     Abstract available
     
     
     
106. BABICH J, Kostakoglu L
     New Approaches in Radiopharmaceutical Development: John Babich Talks with Lale Kostakoglu About Current and Coming Trends in Diagnostics and Therapeutics.
     J Nucl Med. 2025 Feb 13:jnumed.125.269492. doi: 10.2967/jnumed.125.269492.
     PubMed    
     
     
     
107. SUN L, Sun Y, Zuo K, Fan L, et al
     Pilot Study of Nectin-4-Targeted PET Imaging Agent (68)Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human.
     J Nucl Med. 2025 Feb 13:jnumed.124.269024. doi: 10.2967/jnumed.124.269024.
     PubMed     Abstract available
     
     
     
108. CZERNIN J, Bodei L, Modlin I, Calais J, et al
     Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually).
     J Nucl Med. 2025 Feb 6:jnumed.124.269401. doi: 10.2967/jnumed.124.269401.
     PubMed    
     
     
     
109. LASSEN ML, Kertesz H, Rausch I, Panin V, et al
     Positron Range Correction Helps Enhance the Image Quality of Cardiac (82)Rb PET/CT.
     J Nucl Med. 2025 Feb 6:jnumed.124.267855. doi: 10.2967/jnumed.124.267855.
     PubMed     Abstract available
     
     
     
110. MORAITIS A, Kahl T, Kandziora J, Jentzen W, et al
     Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy.
     J Nucl Med. 2025 Feb 6:jnumed.124.268719. doi: 10.2967/jnumed.124.268719.
     PubMed     Abstract available
     
     
     
111. DERLIN T, Widjaja L, Harke NN, Czerner C, et al
     (99m)Tc-MIP-1404 SPECT/CT Companion Diagnostic for (177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2025 Feb 6:jnumed.124.269319. doi: 10.2967/jnumed.124.269319.
     PubMed     Abstract available
     
     
     
112. VAN DER GAAG S, Vis AN, Bartelink IH, Koppes JCC, et al
     Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET.
     J Nucl Med. 2025 Feb 6:jnumed.124.268340. doi: 10.2967/jnumed.124.268340.
     PubMed     Abstract available
     
     
     
113. GHEYSENS O, Pelletier-Galarneau M, Treglia G, Israel O, et al
     Summary: EANM/SNMMI Release Joint Guideline/Procedure Standard for [(18)F]FDG Hybrid PET Use in Infection and Inflammation in Adults, Version 2.0.
     J Nucl Med. 2025 Feb 6:jnumed.125.269538. doi: 10.2967/jnumed.125.269538.
     PubMed    
     
     
     
114. LINDENBERG L, Hope TA, Lin FI, Rowe SP, et al
     Safety, Dosimetry, and Feasibility of [(68)Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
     J Nucl Med. 2025 Feb 6:jnumed.124.268318. doi: 10.2967/jnumed.124.268318.
     PubMed     Abstract available
     
     
     
115. OGATA A, Ikenuma H, Yasuno F, Nihashi T, et al
     First-in-Human Study of [(11)C]NCGG401 for Imaging Colony-Stimulating Factor 1 Receptors in the Brain.
     J Nucl Med. 2025;66:302-308.
     PubMed     Abstract available
     
     
     
116. OLAFSON E, Tonietto M, Klein G, Teng E, et al
     In Vivo Head-to-Head Comparison of [(18)F]GTP1 with [(18)F]MK-6240 and [(18)F]PI-2620 in Alzheimer Disease.
     J Nucl Med. 2025;66:277-285.
     PubMed     Abstract available
     
     
     
117. SONG Y, Lee JH, Kim HK, Lee JH, et al
     Longitudinal Trajectory of Dopamine and Serotonin Transporters in Parkinson Disease.
     J Nucl Med. 2025;66:286-292.
     PubMed     Abstract available
     
     
     
118. OH M, Brumberg J, Sossi V, Varrone A, et al
     Preserved Serotonin Transporter Availability in Parkinson Disease Measured with Either [(11)C]MADAM or [(11)C]DASB: A Study Including 2 Separate Cohorts of Nondepressed Patients.
     J Nucl Med. 2025;66:309-314.
     PubMed     Abstract available
     
     
     January 2025
119. WANG X, Dong Y, Zhang S
     China's Innovations in Nuclear Medicine: Global Insights into Clinical Advancements and Impact.
     J Nucl Med. 2025 Jan 30:jnumed.124.269185. doi: 10.2967/jnumed.124.269185.
     PubMed    
     
     
     
120. MIEDERER I, Buchholz HG, Rademacher L, Eckart C, et al
     Dopaminergic Mechanisms of Cognitive Flexibility: An [(18)F]Fallypride PET Study.
     J Nucl Med. 2025 Jan 30:jnumed.124.268317. doi: 10.2967/jnumed.124.268317.
     PubMed     Abstract available
     
     
     
121. ULANER GA, Lewis J, Landgren O
     CD38-Targeted (89)Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care.
     J Nucl Med. 2025 Jan 30:jnumed.124.269393. doi: 10.2967/jnumed.124.269393.
     PubMed    
     
     
     
122. STRIGARI L, Schwarz J, Bradshaw T, Brosch-Lenz J, et al
     Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins.
     J Nucl Med. 2025 Jan 23:jnumed.124.268186. doi: 10.2967/jnumed.124.268186.
     PubMed     Abstract available
     
     
     
123. VAN GEEL JJL, Moustaquim J, Boers J, Elias SG, et al
     Intrapatient 16alpha-[(18)F]Fluoro-17beta-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
     J Nucl Med. 2025 Jan 23:jnumed.124.268984. doi: 10.2967/jnumed.124.268984.
     PubMed     Abstract available
     
     
     
124. WANG R, Huang M, Wang W, Li M, et al
     Preclinical Evaluation of (68)Ga/(177)Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy.
     J Nucl Med. 2025 Jan 23:jnumed.124.268689. doi: 10.2967/jnumed.124.268689.
     PubMed     Abstract available
     
     
     
125. LAWAL IO, Mushtaq A, Jani AB, Rupji M, et al
     Diuresis During (18)F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.
     J Nucl Med. 2025 Jan 23:jnumed.124.268574. doi: 10.2967/jnumed.124.268574.
     PubMed     Abstract available
     
     
     
126. YAN X, Noergaard M, Morse CL, Liow JS, et al
     PET Quantification in Healthy Humans of Cyclooxygenase-2, a Potential Biomarker of Neuroinflammation.
     J Nucl Med. 2025 Jan 23:jnumed.124.268525. doi: 10.2967/jnumed.124.268525.
     PubMed     Abstract available
     
     
     
127. VEIT-HAIBACH P, Herrmann K, Zimmermann R, Hustinx R, et al
     Green Nuclear Medicine and Radiotheranostics.
     J Nucl Med. 2025 Jan 23:jnumed.124.268928. doi: 10.2967/jnumed.124.268928.
     PubMed     Abstract available
     
     
     
128. BAILEY DL, Willowson KP, O'Keefe G, Goodman S, et al
     A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides.
     J Nucl Med. 2025 Jan 16:jnumed.124.268578. doi: 10.2967/jnumed.124.268578.
     PubMed     Abstract available
     
     
     
129. ENKE JS, Reitsam NG, Dintner S, Liesche-Starnecker F, et al
     Comprehensive Characterization via Molecular Imaging, Longitudinal Multisite Sampling, and Autoptic Work-up in Advanced Small Cell Lung Cancer Undergoing SSTR-Directed Radiopharmaceutical Therapy.
     J Nucl Med. 2025 Jan 16:jnumed.124.268513. doi: 10.2967/jnumed.124.268513.
     PubMed     Abstract available
     
     
     
130. BARBRY F, Chevalier B, Beron A, Lion G, et al
     Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [(18)F]FDG PET/CT and (131)I Posttreatment Scanning.
     J Nucl Med. 2025 Jan 16:jnumed.124.268539. doi: 10.2967/jnumed.124.268539.
     PubMed    
     
     
     
131. CERIANI L, Milan L, Pirosa MC, Martelli M, et al
     PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient Cohort.
     J Nucl Med. 2025 Jan 16:jnumed.124.268874. doi: 10.2967/jnumed.124.268874.
     PubMed     Abstract available
     
     
     
132. PRASAD N, Harris E, DeFilippis EM, Sayer G, et al
     PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft Vasculopathy Progression and Clinical Outcomes.
     J Nucl Med. 2025 Jan 16:jnumed.124.268713. doi: 10.2967/jnumed.124.268713.
     PubMed     Abstract available
     
     
     
133. GAO M, Daube-Witherspoon ME, Karp JS, Surti S, et al
     Total-Body PET System Designs with Axial and Transverse Gaps: A Study of Lesion Quantification and Detectability.
     J Nucl Med. 2025 Jan 16:jnumed.124.267769. doi: 10.2967/jnumed.124.267769.
     PubMed     Abstract available
     
     
     
134. LANGEN KJ, Stoffels G, Filss CP, Kocher M, et al
     Borderline Findings in O-(2-[(18)F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice.
     J Nucl Med. 2025 Jan 16:jnumed.124.268768. doi: 10.2967/jnumed.124.268768.
     PubMed     Abstract available
     
     
     
135. RAMOS-TORRES KM, Conti S, Zhou YP, Tiss A, et al
     Imaging Demyelinated Axons After Spinal Cord Injuries with PET Tracer [(18)F]3F4AP.
     J Nucl Med. 2025 Jan 16:jnumed.124.268242. doi: 10.2967/jnumed.124.268242.
     PubMed     Abstract available
     
     
     
136. VON GUGGENBERG E, di Santo G, Uprimny C, Bayerschmidt S, et al
     Safety, Biodistribution, and Radiation Dosimetry of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
     J Nucl Med. 2025 Jan 16:jnumed.124.268877. doi: 10.2967/jnumed.124.268877.
     PubMed     Abstract available
     
     
     
137. VRAKA C, Homolya M, Ozer O, Spittler A, et al
     RadioFlow Cytometry Reveals That [(18)F]FDG Uptake in K-RAS Lung Cancer Is Driven by Immune Cells: An Analysis on a Single-Cell Level.
     J Nucl Med. 2025 Jan 16:jnumed.124.268799. doi: 10.2967/jnumed.124.268799.
     PubMed     Abstract available
     
     
     
138. RABINOVICI GD, Knopman DS, Arbizu J, Benzinger TLS, et al
     Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
     J Nucl Med. 2025 Jan 8:jnumed.124.268756. doi: 10.2967/jnumed.124.268756.
     PubMed     Abstract available
     
     
     
139. MADSEN C, Fuglo D, Pedersen M, Broholm R, et al
     Prospective Head-to-Head Comparison of (18)F-PSMA PET/CT and (18)F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer.
     J Nucl Med. 2025 Jan 8:jnumed.124.268275. doi: 10.2967/jnumed.124.268275.
     PubMed     Abstract available
     
     
     
140. MILLER SR, Gonzalez RT, Jackson WC, Caram MEV, et al
     Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System.
     J Nucl Med. 2025;66:75-83.
     PubMed     Abstract available
     
     
     
141. UNTERRAINER LM, Hope TA, Fendler WP, Grogan T, et al
     Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
     J Nucl Med. 2025;66:54-60.
     PubMed     Abstract available
     
     
     
142. MILLER RJH, Patel KK, Kwiecinski J, Slipczuk L, et al
     Nuclear Cardiology Surrogate Biomarkers in Clinical Trials.
     J Nucl Med. 2025;66:4-11.
     PubMed     Abstract available
     
     
     
143. HOU P, Chen H, Liang S, Guo W, et al
     Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension.
     J Nucl Med. 2025;66:98-103.
     PubMed     Abstract available
     
     
     
144. BARTEL T
     2024 SNMMI Highlights Lecture: General Clinical Specialties.
     J Nucl Med. 2025;66:158-161.
     PubMed     Abstract available
     
     
     
145. MICHNO M, Schmitz J, Foerges AL, Beer S, et al
     Effect of Acute Hypoxia Exposure on the Availability of A(1) Adenosine Receptors and Perfusion in the Human Brain.
     J Nucl Med. 2025;66:142-149.
     PubMed     Abstract available
     
     
     
146. OMIDVARI N, Shanina E, Leung EK, Sun X, et al
     Quantitative Accuracy Assessment of the NeuroEXPLORER for Diverse Imaging Applications: Moving Beyond Standard Evaluations.
     J Nucl Med. 2025;66:150-157.
     PubMed     Abstract available
     
     
     
147. PARIHAR AS, Mhlanga JC, Royal HD, Siegel BA, et al
     Comparability of Quantifying Relative Lung Ventilation with Inhaled (99m)Tc-Technegas and (133)Xe in Patients Undergoing Evaluation for Lung Transplantation.
     J Nucl Med. 2025;66:104-109.
     PubMed     Abstract available
     
     
     
148. GHAZANFARI N, Liow JS, Kim MJ, Cureton R, et al
     [(11)C]PS13 Demonstrates Pharmacologically Selective and Substantial Binding to Cyclooxygenase-1 in the Human Brain.
     J Nucl Med. 2025;66:117-122.
     PubMed     Abstract available
     
     
     
149. SCHWEIGER L, Maurer T, Simon R, Horn T, et al
     Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery.
     J Nucl Med. 2025;66:67-72.
     PubMed     Abstract available
     
     
     
150. GOTO T, Kikuchi S, Sakurai Y, Tsuruta Y, et al
     Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure.
     J Nucl Med. 2025 Jan 2:jnumed.124.268638. doi: 10.2967/jnumed.124.268638.
     PubMed     Abstract available
     
     
     
151. EMMETT L
     SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy.
     J Nucl Med. 2025 Jan 2:jnumed.124.268325. doi: 10.2967/jnumed.124.268325.
     PubMed    
     
     
     December 2024
152. CHENG K, Ge L, Song M, Li W, et al
     Preclinical Evaluation and Pilot Clinical Study of CD137 PET Radiotracer for Noninvasive Monitoring Early Responses of Immunotherapy.
     J Nucl Med. 2024 Dec 12:jnumed.124.268068. doi: 10.2967/jnumed.124.268068.
     PubMed     Abstract available
     
     
     
153. ROUSSEAU JA, Maier M, Ait-Mohand S, Dumulon-Perreault V, et al
     Antibody-Based PET Imaging of Misfolded Superoxide Dismutase 1 in an Amyotrophic Lateral Sclerosis Mouse Model.
     J Nucl Med. 2024 Dec 12:jnumed.124.268343. doi: 10.2967/jnumed.124.268343.
     PubMed     Abstract available
     
     
     
154. WEEKS JK, Pantel AR, Gitto SB, Liu F, et al
     [(18)F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [(18)F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.
     J Nucl Med. 2024 Dec 5:jnumed.124.267627. doi: 10.2967/jnumed.124.267627.
     PubMed     Abstract available
     
     
     
155. VAN DER WEIJDEN CWJ, Ahmed AKMA, van der Hoorn A, Zhu J, et al
     Myelin Imaging of the Spinal Cord in Animal Models and Patients with Multiple Sclerosis Using [(11)C]MeDAS PET: A Translational Study.
     J Nucl Med. 2024 Dec 5:jnumed.123.266896. doi: 10.2967/jnumed.123.266896.
     PubMed     Abstract available
     
     
     
156. CUTLER CS
     A Banner Year for Nuclear Medicine, Molecular Imaging, and Theranostics.
     J Nucl Med. 2024;65:7A-8A.
     PubMed    
     
     
     
157. VERGOTE VKJ, Verhoef G, Janssens A, Woei-A-Jin FJSH, et al
     International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume-Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma.
     J Nucl Med. 2024;65:1876-1883.
     PubMed     Abstract available
     
     
     
158. MICHALSKI K, Kosmala A, Hartrampf PE, Heinrich M, et al
     [(18)F]FDG and [(68)Ga]Ga-FAPI-04-Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms.
     J Nucl Med. 2024;65:1899-1903.
     PubMed     Abstract available
     
     
     November 2024
159. HOPE TA, Calais J, Goenka AH, Haberkorn U, et al
     SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET.
     J Nucl Med. 2024 Nov 21:jnumed.124.269002. doi: 10.2967/jnumed.124.269002.
     PubMed    
     
     
     
160. JACENE H, Czernin J
     Solving Challenging Puzzles: Heather Jacene Talks with Johannes Czernin About Leadership in Clinical Nuclear Medicine and the SNMMI.
     J Nucl Med. 2024 Nov 21:jnumed.124.269029. doi: 10.2967/jnumed.124.269029.
     PubMed    
     
     
     
161. ERMIS E, Bachmann N, Lutz K, Pyka T, et al
     Meningioma Revisited: Should Whole-Body Staging with [(68)Ga]Ga-DOTATOC PET/CT of High-Grade Meningiomas Become Standard Practice?
     J Nucl Med. 2024 Nov 21:jnumed.124.267934. doi: 10.2967/jnumed.124.267934.
     PubMed    
     
     
     
162. DEMIRCI RA, Ghodsi A, Gulati R, Behnia S, et al
     PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received (177)Lu-PSMA-617: Importance of (18)F-FDG-Avid Discordant Findings.
     J Nucl Med. 2024 Nov 14:jnumed.124.268167. doi: 10.2967/jnumed.124.268167.
     PubMed     Abstract available
     
     
     
163. WENZEL M, Koll F, Hoeh B, Humke C, et al
     Real-World Comparison of Cabazitaxel Versus (177)Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2024 Nov 14:jnumed.124.268807. doi: 10.2967/jnumed.124.268807.
     PubMed     Abstract available
     
     
     
164. COLLIJ LE, Bischof GN, Altomare D, Bader I, et al
     Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study.
     J Nucl Med. 2024 Nov 14:jnumed.124.268119. doi: 10.2967/jnumed.124.268119.
     PubMed     Abstract available
     
     
     
165. LOU K, Wang J, He H, Wang Y, et al
     Value of [(68)Ga]Ga-NYM046 PET/CT, in Comparison with (18)F-FDG PET/CT, for Diagnosis of Clear Cell Renal Cell Carcinoma.
     J Nucl Med. 2024 Nov 14:jnumed.124.267527. doi: 10.2967/jnumed.124.267527.
     PubMed     Abstract available
     
     
     
166. HUANG W, Cao M, Wu Y, Zhang Y, et al
     Immuno-PET/CT Imaging of Trop2 with [(18)F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation.
     J Nucl Med. 2024 Nov 14:jnumed.124.268751. doi: 10.2967/jnumed.124.268751.
     PubMed     Abstract available
     
     
     
167. DEMIRCI RA, Gulati R, Hawley JE, Yezefski T, et al
     SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
     J Nucl Med. 2024 Nov 7:jnumed.124.267665. doi: 10.2967/jnumed.124.267665.
     PubMed     Abstract available
     
     
     
168. ZHANG H, Ren C, Liu Y, Yan X, et al
     Performance Characteristics of a New Generation 148-cm Axial Field-of-View uMI Panorama GS PET/CT System with Extended NEMA NU 2-2018 and EARL Standards.
     J Nucl Med. 2024 Nov 7:jnumed.124.267963. doi: 10.2967/jnumed.124.267963.
     PubMed     Abstract available
     
     
     
169. ZHOU X, Wu Q, Zhai W, Zhang Y, et al
     CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study.
     J Nucl Med. 2024 Nov 7:jnumed.124.268509. doi: 10.2967/jnumed.124.268509.
     PubMed     Abstract available
     
     
     
170. KONIAR H, Wharton L, Ingham A, Morales Oliver AP, et al
     Preclinical Evaluation of (226)Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy.
     J Nucl Med. 2024;65:1762-1768.
     PubMed     Abstract available
     
     
     October 2024
171. SONNI I, Weiner AB, Doddipalli S, Deol M, et al
     Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI.
     J Nucl Med. 2024 Oct 30:jnumed.124.268443. doi: 10.2967/jnumed.124.268443.
     PubMed     Abstract available
     
     
     
172. YOUNG AJ, Pantel AR, Kiani M, Doot RK, et al
     Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted (18)F-Fluorthanatrace PET in Breast Cancer.
     J Nucl Med. 2024 Oct 30:jnumed.124.268254. doi: 10.2967/jnumed.124.268254.
     PubMed     Abstract available
     
     
     
173. HUANG RR, Zuo C, Mona CE, Holzgreve A, et al
     FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
     J Nucl Med. 2024 Oct 30:jnumed.124.268037. doi: 10.2967/jnumed.124.268037.
     PubMed     Abstract available
     
     
     
174. SWIHA M, Pathmanandavel S, Papa N, Sabahi Z, et al
     Comparison of Posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2024 Oct 30:jnumed.124.267606. doi: 10.2967/jnumed.124.267606.
     PubMed     Abstract available
     
     
     
175. HELISCH A, Kratochwil C, Kleist C, Kramer S, et al
     Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with (213)Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors.
     J Nucl Med. 2024 Oct 30:jnumed.124.268386. doi: 10.2967/jnumed.124.268386.
     PubMed     Abstract available
     
     
     
176. WANG R, Kang W, Liu Z, Zheng Y, et al
     Head-to-Head Comparison of [(68)Ga]Ga-NOTA-RM26 and [(18)F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study.
     J Nucl Med. 2024 Oct 24:jnumed.124.267810. doi: 10.2967/jnumed.124.267810.
     PubMed     Abstract available
     
     
     
177. MORRIS ED, Emvalomenos GM, Hoye J, Meikle SR, et al
     Modeling PET Data Acquired During Nonsteady Conditions: What If Brain Conditions Change During the Scan?
     J Nucl Med. 2024 Oct 24:jnumed.124.267494. doi: 10.2967/jnumed.124.267494.
     PubMed     Abstract available
     
     
     
178. KATUGAMPOLA S, Wang J, Howell RW
     MIRD Pamphlet No. 31: MIRDcell V4-Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy.
     J Nucl Med. 2024 Oct 24:jnumed.123.267238. doi: 10.2967/jnumed.123.267238.
     PubMed     Abstract available
     
     
     
179. LEVI J, Das M, Vasanawala MS, Behl D, et al
     [(18)F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.
     J Nucl Med. 2024 Oct 24:jnumed.124.268253. doi: 10.2967/jnumed.124.268253.
     PubMed     Abstract available
     
     
     
180. AMEREIN A, Maurer C, Kircher M, Gable A, et al
     Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy.
     J Nucl Med. 2024 Oct 24:jnumed.124.268217. doi: 10.2967/jnumed.124.268217.
     PubMed     Abstract available
     
     
     
181. BOSS M, Eriksson O, Mikkola K, Eek A, et al
     Improved Localization of Insulinomas Using (68)Ga-NODAGA-Exendin-4 PET/CT.
     J Nucl Med. 2024 Oct 17:jnumed.124.268158. doi: 10.2967/jnumed.124.268158.
     PubMed     Abstract available
     
     
     
182. ARBIZU J, Morbelli S, Minoshima S, Barthel H, et al
     SNMMI Procedure Standard/EANM Practice Guideline for Brain [(18)F]FDG PET Imaging, Version 2.0.
     J Nucl Med. 2024 Oct 17:jnumed.124.268754. doi: 10.2967/jnumed.124.268754.
     PubMed     Abstract available
     
     
     
183. JANNUSCH K, Umutlu L, Kirchner J, Bruckmann NM, et al
     Impact of (18)F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial.
     J Nucl Med. 2024 Oct 10:jnumed.124.268065. doi: 10.2967/jnumed.124.268065.
     PubMed     Abstract available
     
     
     
184. LIU Q, Xu X, Yang Z, Zhang J, et al
     Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer.
     J Nucl Med. 2024 Oct 10:jnumed.124.267529. doi: 10.2967/jnumed.124.267529.
     PubMed     Abstract available
     
     
     
185. GAFITA A, Menard AR, Solnes LB
     Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care.
     J Nucl Med. 2024 Oct 10:jnumed.124.268608. doi: 10.2967/jnumed.124.268608.
     PubMed    
     
     
     
186. HOTTA M, Kim GHJ, Rerkpichaisuth V, Teng PY, et al
     Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease.
     J Nucl Med. 2024 Oct 3:jnumed.124.268351. doi: 10.2967/jnumed.124.268351.
     PubMed     Abstract available
     
     
     
187. PELLETIER-GALARNEAU M, Simard F, Tadros R, Tremblay-Gravel M, et al
     Arrhythmias in Nongranulomatous Myocarditis: Is There a Role for PET?
     J Nucl Med. 2024 Oct 3:jnumed.124.268033. doi: 10.2967/jnumed.124.268033.
     PubMed    
     
     
     
188. PRATT EC, Mezzadra R, Kulick A, Kaminsky S, et al
     uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence.
     J Nucl Med. 2024 Oct 3:jnumed.124.268278. doi: 10.2967/jnumed.124.268278.
     PubMed     Abstract available
     
     
     
189. FERRANDEZ MC, Golla SSV, Eertink JJ, Wiegers SE, et al
     Validation of an Artificial Intelligence-Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma.
     J Nucl Med. 2024 Oct 3:jnumed.124.268191. doi: 10.2967/jnumed.124.268191.
     PubMed     Abstract available
     
     
     
190. CARLSEN EA, Loft M, Johnbeck CB, Knigge U, et al
     Routine Use of [(64)Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans.
     J Nucl Med. 2024 Oct 3:jnumed.124.267939. doi: 10.2967/jnumed.124.267939.
     PubMed     Abstract available
     
     
     
191. CALAIS J, Morris MJ, Kendi AT, Kalebasty AR, et al
     Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
     J Nucl Med. 2024 Oct 3:jnumed.124.268363. doi: 10.2967/jnumed.124.268363.
     PubMed     Abstract available
     
     
     
192. LEE H, Alhamshari AS, Patel V, Bhattaru A, et al
     Cardiac Neuroendocrine Tumor Metastases on (68)Ga-DOTATATE PET/CT: Identification and Prognostic Significance.
     J Nucl Med. 2024 Oct 3:jnumed.124.267948. doi: 10.2967/jnumed.124.267948.
     PubMed     Abstract available
     
     
     
193. MILLER RJH, Lemley M, Shanbhag A, Ramirez G, et al
     The Updated Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT 2.0).
     J Nucl Med. 2024 Oct 3:jnumed.124.268292. doi: 10.2967/jnumed.124.268292.
     PubMed     Abstract available
     
     
     
194. PISANO G, van Oosterom MN, Berrens AC, Slof LJ, et al
     Freehand SPECT Combined with 3-Dimensional Light Detection and Ranging as Alternative Means of Specimen Scanning During Prostate Cancer Surgery.
     J Nucl Med. 2024 Oct 3:jnumed.124.268256. doi: 10.2967/jnumed.124.268256.
     PubMed    
     
     
     
195. RYU J, Hyung J, Han S, Jeong JH, et al
     Impact of (18)F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer.
     J Nucl Med. 2024 Oct 3:jnumed.124.267913. doi: 10.2967/jnumed.124.267913.
     PubMed     Abstract available
     
     
     
196. ZHANG X, Lin Z, Feng Y, Lin Z, et al
     Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer with [(68)Ga]Ga-FAPI-04 PET, [(18)F]FDG PET, and Contrast-Enhanced MRI: Lesion-to-Lesion Comparison with Pathology.
     J Nucl Med. 2024;65:1548-1556.
     PubMed     Abstract available
     
     
     
197. VAN SLUIS J, van Snick JH, Glaudemans AWJM, Slart RHJA, et al
     Ultrashort Oncologic Whole-Body [(18)F]FDG Patlak Imaging Using LAFOV PET.
     J Nucl Med. 2024;65:1652-1657.
     PubMed     Abstract available
     
     
     
198. ENKE JS, Ritzel K, Asbach E, Reitsam NG, et al
     C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy Using [(99m)Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study.
     J Nucl Med. 2024;65:1640-1644.
     PubMed     Abstract available
     
     
     
199. ROOHANI B, Mendez AS, Dangarwala M, Katz S, et al
     Nuclear Imaging of Bispecific Antibodies on the Rise.
     J Nucl Med. 2024;65:1512-1517.
     PubMed     Abstract available
     
     
     September 2024
200. DONG Y, Wang Z, Hu X, Sun Y, et al
     [(18)F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial.
     J Nucl Med. 2024 Sep 26:jnumed.124.268557. doi: 10.2967/jnumed.124.268557.
     PubMed     Abstract available
     
     
     
201. BERNARDINO RM, Lajkosz K, Yin LB, Sayyid RK, et al
     Association of Free-to-Total PSA Ratio and (18)F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
     J Nucl Med. 2024 Sep 26:jnumed.124.267877. doi: 10.2967/jnumed.124.267877.
     PubMed     Abstract available
     
     
     
202. POULIOT F, Saad F, Rousseau E, Richard PO, et al
     Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
     J Nucl Med. 2024 Sep 26:jnumed.124.268020. doi: 10.2967/jnumed.124.268020.
     PubMed     Abstract available
     
     
     
203. PALESTRO CJ, Abikhzer G, Bar-Sever Z, Bartel T, et al
     Summary: Appropriate Use Criteria for the Use of Nuclear Medicine in Fever of Unknown Origin.
     J Nucl Med. 2024 Sep 26:jnumed.124.268797. doi: 10.2967/jnumed.124.268797.
     PubMed     Abstract available
     
     
     
204. BYUN JW, Paeng JC, Kim YJ, Lee SP, et al
     Evaluation of Fibroblast Activation Protein Expression Using (68)Ga-FAPI46 PET in Hypertension-Induced Tissue Changes.
     J Nucl Med. 2024 Sep 26:jnumed.124.267489. doi: 10.2967/jnumed.124.267489.
     PubMed     Abstract available
     
     
     
205. JADVAR H, Iravani A, Bodei L, Calais J, et al
     Challenges with (177)Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice.
     J Nucl Med. 2024 Sep 19:jnumed.124.268023. doi: 10.2967/jnumed.124.268023.
     PubMed    
     
     
     
206. YOUNG JJ, O'Dell RS, Naganawa M, Toyonaga T, et al
     Validation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [(11)C]UCB-J PET.
     J Nucl Med. 2024 Sep 19:jnumed.124.267419. doi: 10.2967/jnumed.124.267419.
     PubMed     Abstract available
     
     
     
207. TUNCER O, Steinberger D, Steiner J, Hinojos M, et al
     Quantitative SPECT/CT Metrics in Early Prediction of [(177)Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients.
     J Nucl Med. 2024 Sep 12:jnumed.124.267964. doi: 10.2967/jnumed.124.267964.
     PubMed     Abstract available
     
     
     
208. POOT AJ, Lapa C, Weber WA, Lam MGEH, et al
     [(68)Ga]Ga-RAYZ-8009: A Glypican-3-Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging-A First-in-Human Case Series.
     J Nucl Med. 2024 Sep 12:jnumed.124.268147. doi: 10.2967/jnumed.124.268147.
     PubMed     Abstract available
     
     
     
209. METSER U, Nunez JE, Chan D, Kulanthaivelu R, et al
     Dual Somatostatin Receptor/(18)F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors.
     J Nucl Med. 2024 Sep 12:jnumed.124.267982. doi: 10.2967/jnumed.124.267982.
     PubMed     Abstract available
     
     
     
210. AL-IBRAHEEM A, Abdlkadir A, Herrmann K, Bomanji J, et al
     Diagnostic Accuracy of [(18)F]FDG PET/MRI in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Metaanalysis.
     J Nucl Med. 2024 Sep 12:jnumed.124.268049. doi: 10.2967/jnumed.124.268049.
     PubMed     Abstract available
     
     
     
211. ALAKONYA H, Koustoulidou S, Hopkins SL, Veal M, et al
     Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT.
     J Nucl Med. 2024 Sep 12:jnumed.124.267736. doi: 10.2967/jnumed.124.267736.
     PubMed     Abstract available
     
     
     
212. GALBIATI A, Bocci M, Ravazza D, Mock J, et al
     Preclinical Evaluation of (177)Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors.
     J Nucl Med. 2024 Sep 12:jnumed.124.268200. doi: 10.2967/jnumed.124.268200.
     PubMed     Abstract available
     
     
     
213. POTY S, Ordas L, Dekempeneer Y, Parach AA, et al
     Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting.
     J Nucl Med. 2024 Sep 12:jnumed.124.267624. doi: 10.2967/jnumed.124.267624.
     PubMed     Abstract available
     
     
     
214. WRAY R, Mauguen A, Michaud L, Leithner D, et al
     Development of (18)F-Fluoromisonidazole Hypoxia PET/CT Diagnostic Interpretation Criteria and Validation of Interreader Reliability, Reproducibility, and Performance.
     J Nucl Med. 2024 Sep 12:jnumed.124.267775. doi: 10.2967/jnumed.124.267775.
     PubMed     Abstract available
     
     
     
215. SULLIVAN R, Hou J, Yu L, Wilk B, et al
     Design, Synthesis, and Preclinical Evaluation of a High-Affinity (18)F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction.
     J Nucl Med. 2024 Sep 12:jnumed.124.267578. doi: 10.2967/jnumed.124.267578.
     PubMed     Abstract available
     
     
     
216. SIVAKUMARAN T, Cardin A, Callahan J, Wong HL, et al
     Evaluating the Utility of (18)F-FDG PET/CT in Cancer of Unknown Primary.
     J Nucl Med. 2024 Sep 5:jnumed.123.267274. doi: 10.2967/jnumed.123.267274.
     PubMed     Abstract available
     
     
     
217. EISSES B, van Geel JJL, Brouwers AH, Bensch F, et al
     Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
     J Nucl Med. 2024 Sep 5:jnumed.124.267636. doi: 10.2967/jnumed.124.267636.
     PubMed     Abstract available
     
     
     
218. BAUCKNEHT M, D'Amico F, Albano D, Balma M, et al
     Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [(18)F]PSMA-1007 PET/CT.
     J Nucl Med. 2024 Sep 5:jnumed.124.267751. doi: 10.2967/jnumed.124.267751.
     PubMed     Abstract available
     
     
     
219. KULKARNI HR, Maupin KA, Brennan T, Forsberg J, et al
     First-in-Human Total-Body PET/CT Imaging Using (89)Zr-Labeled MUC5AC Antibody in a Patient with Pancreatic Adenocarcinoma.
     J Nucl Med. 2024 Sep 5:jnumed.124.268074. doi: 10.2967/jnumed.124.268074.
     PubMed    
     
     
     
220. 
     Robert Carretta, MD, 1941-2023.
     J Nucl Med. 2024;65:1498.
     PubMed    
     
     
     
221. BEHRENBRUCH C
     FINDing the Future of Radiopharma.
     J Nucl Med. 2024;65:1333-1335.
     PubMed    
     
     
     August 2024
222. KIM D, Kang SK, Shin SA, Choi H, et al
     Improving (18)F-FDG PET Quantification Through a Spatial Normalization Method.
     J Nucl Med. 2024 Aug 29:jnumed.123.267360. doi: 10.2967/jnumed.123.267360.
     PubMed     Abstract available
     
     
     
223. MWANIA MM, Gitau SN, Shah J, Makhdomi K, et al
     Association Between CA 15-3 and (18)F-FDG PET/CT Findings in Recurrent Breast Cancer Patients at a Tertiary Referral Hospital in Kenya.
     J Nucl Med. 2024 Aug 29:jnumed.124.267851. doi: 10.2967/jnumed.124.267851.
     PubMed     Abstract available
     
     
     
224. THIN P, Hotta M, Gafita A, Grogan T, et al
     Clinical Factors That Influence Repeat (68)Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative (68)Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
     J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591.
     PubMed     Abstract available
     
     
     
225. HO KV, Tatum DS, Watkinson L, Carmack T, et al
     Single Chelator-Minibody Theranostic Agents for (89)Zr PET Imaging and (177)Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
     J Nucl Med. 2024 Aug 14:jnumed.124.267667. doi: 10.2967/jnumed.124.267667.
     PubMed     Abstract available
     
     
     
226. INCE S, Laforest R, Itani M, Prasad V, et al
     Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?
     J Nucl Med. 2024 Aug 14:jnumed.123.266469. doi: 10.2967/jnumed.123.266469.
     PubMed     Abstract available
     
     
     
227. PANDIT-TASKAR N, Zanzonico PB, Grkovski M, Donzelli M, et al
     Theranostic Intratumoral Convection-Enhanced Delivery of (124)I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry.
     J Nucl Med. 2024 Aug 14:jnumed.123.266365. doi: 10.2967/jnumed.123.266365.
     PubMed     Abstract available
     
     
     
228. MAINTA IC, Neroladaki A, Wolf NB, Benamran D, et al
     [(68)Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria.
     J Nucl Med. 2024 Aug 8:jnumed.124.267899. doi: 10.2967/jnumed.124.267899.
     PubMed     Abstract available
     
     
     
229. YADAV S, Lowery B, Tuchayi AM, Jiang F, et al
     Impact of Posttreatment SPECT/CT on Patient Management During (177)Lu-PSMA-617 Radiopharmaceutical Therapy.
     J Nucl Med. 2024 Aug 8:jnumed.124.267955. doi: 10.2967/jnumed.124.267955.
     PubMed     Abstract available
     
     
     
230. OSMAN MM, Iravani A, Mitchell C, Hicks RJ, et al
     (18)F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology.
     J Nucl Med. 2024 Aug 1:jnumed.124.267772. doi: 10.2967/jnumed.124.267772.
     PubMed     Abstract available
     
     
     
231. LI S, Nguyen A, Counter W, John NC, et al
     Utility of (64)Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on (68)Ga-PSMA-11 PET/CT.
     J Nucl Med. 2024 Aug 1:jnumed.124.267881. doi: 10.2967/jnumed.124.267881.
     PubMed     Abstract available
     
     
     
232. BOELLAARD R, Buvat I, Nioche C, Ceriani L, et al
     International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline (18)F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation.
     J Nucl Med. 2024 Aug 1:jnumed.124.267789. doi: 10.2967/jnumed.124.267789.
     PubMed     Abstract available
     
     
     
233. NIKITAS J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, et al
     Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2024 Aug 1:jnumed.124.267922. doi: 10.2967/jnumed.124.267922.
     PubMed     Abstract available
     
     
     
234. RIETBERGEN DDD, Buckle T, Slof LJ, van Meerbeek MP, et al
     hHEPATO-Cy5, a Bimodal Tracer for Image-Guided Hepatobiliary Surgery.
     J Nucl Med. 2024;65:1301-1306.
     PubMed     Abstract available
     
     
     
235. SCHELBERT H, Schoder H, Czernin J
     Illuminating Cardiac Function: Heinz Schelbert Talks with Heiko Schoder and Johannes Czernin About a Pioneering Career in Nuclear Cardiology.
     J Nucl Med. 2024;65:1163-1165.
     PubMed    
     
     
     
236. RESCH S, Ziegler SI, Sheikh G, Unterrainer LM, et al
     Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [(177)Lu]Lu-PSMA-I&T Therapy.
     J Nucl Med. 2024;65:1272-1278.
     PubMed     Abstract available
     
     
     
237. ANGAPPULIGE DH, Barashi NS, Pickersgill N, Weimholt C, et al
     Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression.
     J Nucl Med. 2024;65:1210-1216.
     PubMed     Abstract available
     
     
     
238. CAPTIER N, Orlhac F, Hovhannisyan-Baghdasarian N, Luporsi M, et al
     RadShap: An Explanation Tool for Highlighting the Contributions of Multiple Regions of Interest to the Prediction of Radiomic Models.
     J Nucl Med. 2024;65:1307-1312.
     PubMed     Abstract available
     
     
     
239. LUDWIG V, Maliha PG, Shen J, Tonnelet D, et al
     [(68)Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic Lesions.
     J Nucl Med. 2024;65:1328-1329.
     PubMed    
     
     
     July 2024
240. BUDDENKOTTE T, Buchert R
     Unrealistic Data Augmentation Improves the Robustness of Deep Learning-Based Classification of Dopamine Transporter SPECT Against Variability Between Sites and Between Cameras.
     J Nucl Med. 2024 Jul 25:jnumed.124.267570. doi: 10.2967/jnumed.124.267570.
     PubMed     Abstract available
     
     
     
241. PICCARDO A, Bottoni G, Puppo C, Massollo M, et al
     Role of (64)CuCl(2) PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and (18)F-FDG PET/CT.
     J Nucl Med. 2024 Jul 25:jnumed.124.267474. doi: 10.2967/jnumed.124.267474.
     PubMed     Abstract available
     
     
     
242. GEBRE RK, Rial AM, Raghavan S, Wiste HJ, et al
     Advancing Tau PET Quantification in Alzheimer Disease with Machine Learning: Introducing THETA, a Novel Tau Summary Measure.
     J Nucl Med. 2024 Jul 25:jnumed.123.267273. doi: 10.2967/jnumed.123.267273.
     PubMed     Abstract available
     
     
     
243. PIROZZI MA, Gaudieri V, Prinster A, Magliulo M, et al
     StepBrain: A 3-Dimensionally Printed Multicompartmental Anthropomorphic Brain Phantom to Simulate PET Activity Distributions.
     J Nucl Med. 2024 Jul 18:jnumed.123.267277. doi: 10.2967/jnumed.123.267277.
     PubMed     Abstract available
     
     
     
244. BASACO BERNABEU T, Mansi R, Del Pozzo L, Zanger S, et al
     (61)Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
     J Nucl Med. 2024 Jul 18:jnumed.123.267126. doi: 10.2967/jnumed.123.267126.
     PubMed     Abstract available
     
     
     
245. KANG F, Xie Z, Ma W, Quan Z, et al
     Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System.
     J Nucl Med. 2024 Jul 11:jnumed.124.267446. doi: 10.2967/jnumed.124.267446.
     PubMed     Abstract available
     
     
     
246. LARIVE T, Boursier C, Claudin M, Varlot J, et al
     Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis.
     J Nucl Med. 2024 Jul 11:jnumed.123.267219. doi: 10.2967/jnumed.123.267219.
     PubMed     Abstract available
     
     
     
247. CLEMENT C, Leclere JC, Maheo C, Le Pennec R, et al
     Diagnostic Performance of (18)F-FDG PET/CT According to Delay After Treatment to Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma.
     J Nucl Med. 2024 Jul 11:jnumed.124.267391. doi: 10.2967/jnumed.124.267391.
     PubMed     Abstract available
     
     
     
248. KESSLER L, Schwaning F, Metzenmacher M, Pabst K, et al
     Fibroblast Activation Protein-Directed Imaging Outperforms (18)F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.
     J Nucl Med. 2024 Jul 3:jnumed.124.267473. doi: 10.2967/jnumed.124.267473.
     PubMed     Abstract available
     
     
     
249. OSTER C, Kessler L, Blau T, Keyvani K, et al
     The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, (68)Ga-FAPI-46 PET Data, and Survival Data.
     J Nucl Med. 2024 Jul 3:jnumed.123.267151. doi: 10.2967/jnumed.123.267151.
     PubMed     Abstract available
     
     
     
250. BORGWARDT L, Brok J, Andersen KF, Madsen J, et al
     Performing [(18)F]MFBG Long-Axial-Field-of-View PET/CT Without Sedation or General Anesthesia for Imaging of Children with Neuroblastoma.
     J Nucl Med. 2024 Jul 3:jnumed.123.267256. doi: 10.2967/jnumed.123.267256.
     PubMed     Abstract available
     
     
     
251. ELLS Z, Grogan TR, Czernin J, Dahlbom M, et al
     Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.
     J Nucl Med. 2024 Jul 3:jnumed.124.267452. doi: 10.2967/jnumed.124.267452.
     PubMed     Abstract available
     
     
     
252. LU Z, Polan DF, Wei L, Aryal MP, et al
     PET/CT-Based Absorbed Dose Maps in (90)Y Selective Internal Radiation Therapy Correlate with Spatial Changes in Liver Function Derived from Dynamic MRI.
     J Nucl Med. 2024 Jul 3:jnumed.124.267421. doi: 10.2967/jnumed.124.267421.
     PubMed     Abstract available
     
     
     
253. WARFVINGE CF, Gustafsson J, Roth D, Tennvall J, et al
     Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [(177)Lu]Lu-DOTATATE.
     J Nucl Med. 2024;65:1070-1075.
     PubMed     Abstract available
     
     
     June 2024
254. COMBET-CURT V, Buchalet C, Malicot KL, Lemanski C, et al
     Prognostic Value of (18)F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE.
     J Nucl Med. 2024 Jun 27:jnumed.124.267626. doi: 10.2967/jnumed.124.267626.
     PubMed     Abstract available
     
     
     
255. BAUCKNEHT M, Lanfranchi F, Albano D, Triggiani L, et al
     Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
     J Nucl Med. 2024 Jun 27:jnumed.124.267586. doi: 10.2967/jnumed.124.267586.
     PubMed     Abstract available
     
     
     
256. LAVERDIERE I, Matte G, Darveau M, Beauregard JM, et al
     Nuclear Pharmacy Training in the Era of Theranostics: Toward Meeting the Needs of Nuclear Medicine Patients for Comprehensive Pharmaceutical Care.
     J Nucl Med. 2024 Jun 21:jnumed.124.267603. doi: 10.2967/jnumed.124.267603.
     PubMed    
     
     
     
257. LI H, Badawi RD, Cherry SR, Fontaine K, et al
     Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager.
     J Nucl Med. 2024 Jun 13:jnumed.124.267767. doi: 10.2967/jnumed.124.267767.
     PubMed     Abstract available
     
     
     
258. MONASTERO F, Vetrone L, Cardisciani L, Renzulli M, et al
     [(68)Ga]Ga-PSMA-11 PET/CT-Positive Hepatic Inflammatory Pseudotumor: Possible PSMA-Avid Pitfall in Nuclear Imaging.
     J Nucl Med. 2024 Jun 13:jnumed.124.267518. doi: 10.2967/jnumed.124.267518.
     PubMed    
     
     
     
259. FONSECA CABRERA GO, Ma X, Lin W, Zhang T, et al
     Synthesis of (64)Cu-, (55)Co-, and (68)Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles.
     J Nucl Med. 2024 Jun 13:jnumed.124.267469. doi: 10.2967/jnumed.124.267469.
     PubMed     Abstract available
     
     
     
260. MUKKAMALA R, Carlson DJ, Miller NK, Lindeman SD, et al
     Design of a Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy with High Tumor-to-Healthy-Tissue Ratios.
     J Nucl Med. 2024 Jun 13:jnumed.124.267756. doi: 10.2967/jnumed.124.267756.
     PubMed     Abstract available
     
     
     
261. KUO PH, Esposito G, Ulaner GA, Yoo D, et al
     Interreader and Intrareader Reproducibility of (18)F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies.
     J Nucl Med. 2024 Jun 13:jnumed.123.267306. doi: 10.2967/jnumed.123.267306.
     PubMed     Abstract available
     
     
     
262. PHAM TT, Chenoweth A, Patel N, Banu A, et al
     In Vivo PET Imaging of (89)Zr-Labeled Natural Killer Cells and the Modulating Effects of a Therapeutic Antibody.
     J Nucl Med. 2024 Jun 6:jnumed.124.267876. doi: 10.2967/jnumed.124.267876.
     PubMed     Abstract available
     
     
     
263. EVANGELISTA L, Zattoni F, Burei M, Bertin D, et al
     A Prospective Randomized Multicenter Study on the Impact of [(18)F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.
     J Nucl Med. 2024 Jun 6:jnumed.123.267355. doi: 10.2967/jnumed.123.267355.
     PubMed     Abstract available
     
     
     
264. SHIYAM SUNDAR LK, Beyer T
     Is Automatic Tumor Segmentation on Whole-Body (18)F-FDG PET Images a Clinical Reality?
     J Nucl Med. 2024 Jun 6:jnumed.123.267183. doi: 10.2967/jnumed.123.267183.
     PubMed     Abstract available
     
     
     
265. NADEL HR
     Innovation and Dedication Spur Excellence in Nuclear Medicine and Molecular Imaging.
     J Nucl Med. 2024;65:11A-12A.
     PubMed    
     
     
     
266. CZERNIN J
     JNM Editors' Choice Awards for 2023.
     J Nucl Med. 2024;65:825.
     PubMed    
     
     
     
267. BEEKMAN F, Czernin J, Mona C
     Inventing His Own Career Path: Freek Beekman Talks with Johannes Czernin and Christine Mona About Success in Academia and Industry.
     J Nucl Med. 2024;65:826-828.
     PubMed    
     
     
     
268. RICH AA, Taunk NK, Mankoff DA, Pantel AR, et al
     [(18)F]Fluoroestradiol Uptake in Irradiated Lung Parenchyma and Draining Nodes.
     J Nucl Med. 2024;65:990-991.
     PubMed    
     
     
     May 2024
269. LECY EE, Min HK, Apgar CJ, Maltais DD, et al
     Patterns of Early Neocortical Amyloid-beta Accumulation: A PET Population-Based Study.
     J Nucl Med. 2024 May 23:jnumed.123.267150. doi: 10.2967/jnumed.123.267150.
     PubMed     Abstract available
     
     
     
270. IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al
     CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
     J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107.
     PubMed     Abstract available
     
     
     
271. SMEETS EMM, Trajkovic-Arsic M, Geijs D, Karakaya S, et al
     Histology-Based Radiomics for [(18)F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer.
     J Nucl Med. 2024 May 23:jnumed.123.266262. doi: 10.2967/jnumed.123.266262.
     PubMed     Abstract available
     
     
     
272. WATANABE M, Fendler WP, Grafe H, Hirmas N, et al
     Prognostic Implications of (68)Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.
     J Nucl Med. 2024 May 23:jnumed.123.266981. doi: 10.2967/jnumed.123.266981.
     PubMed     Abstract available
     
     
     
273. SADAGHIANI MS, Baskaran S, Gorin MA, Rowe SP, et al
     Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.
     J Nucl Med. 2024 May 23:jnumed.124.267417. doi: 10.2967/jnumed.124.267417.
     PubMed     Abstract available
     
     
     
274. FLEMING MT, Hermsen R, Purysko AS, Chau A, et al
     True-Positive (18)F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study.
     J Nucl Med. 2024 May 23:jnumed.123.267271. doi: 10.2967/jnumed.123.267271.
     PubMed     Abstract available
     
     
     
275. HEIDARI P, Haj-Mirzaian A, Prabhu S, Ataeinia B, et al
     Granzyme B PET Imaging for Assessment of Disease Activity in Inflammatory Bowel Disease.
     J Nucl Med. 2024 May 16:jnumed.123.267344. doi: 10.2967/jnumed.123.267344.
     PubMed     Abstract available
     
     
     
276. YADAV S, Jiang F, Kurkowska S, Saelee R, et al
     Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
     J Nucl Med. 2024 May 9:jnumed.123.267208. doi: 10.2967/jnumed.123.267208.
     PubMed     Abstract available
     
     
     
277. CAOBELLI F, Gozlugol N, Bakula A, Rominger A, et al
     Prognostic Value of [(99m)Tc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and Preserved Left Ventricular Function.
     J Nucl Med. 2024 May 9:jnumed.123.266926. doi: 10.2967/jnumed.123.266926.
     PubMed     Abstract available
     
     
     
278. LANZAFAME H, Mavroeidi IA, Pabst KM, Desaulniers M, et al
     (68)Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy.
     J Nucl Med. 2024 May 9:jnumed.123.267248. doi: 10.2967/jnumed.123.267248.
     PubMed     Abstract available
     
     
     
279. MILLER RJH, Shanbhag A, Michalowska AM, Kavanagh P, et al
     Deep Learning-Enabled Quantification of (99m)Tc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis.
     J Nucl Med. 2024 May 9:jnumed.124.267542. doi: 10.2967/jnumed.124.267542.
     PubMed     Abstract available
     
     
     
280. ZANG J, Yang Y, Chen S, Wang C, et al
     Diagnostic Performance of [(18)F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
     J Nucl Med. 2024 May 9:jnumed.123.266940. doi: 10.2967/jnumed.123.266940.
     PubMed     Abstract available
     
     
     
281. HOEK R, van Diemen PA, Raijmakers PG, Driessen RS, et al
     Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [(15)O]H(2)O PET Imaging.
     J Nucl Med. 2024 May 9:jnumed.123.267195. doi: 10.2967/jnumed.123.267195.
     PubMed     Abstract available
     
     
     
282. DIETZ M, Kamani CH, Bousige C, Dunet V, et al
     Natural History of Myocardial alpha(v)beta(3) Integrin Expression After Acute Myocardial Infarction: Correlation with Changes in Myocardial Blood Flow.
     J Nucl Med. 2024 May 9:jnumed.124.267514. doi: 10.2967/jnumed.124.267514.
     PubMed     Abstract available
     
     
     
283. WU Y, Sun T, Ng YL, Liu J, et al
     Clinical Implementation of Total-Body PET in China.
     J Nucl Med. 2024;65.
     PubMed     Abstract available
     
     
     
284. ZHANG J, Duan X, Chen X, Zhang Z, et al
     Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with (68)Ga-N188.
     J Nucl Med. 2024;65.
     PubMed     Abstract available
     
     
     
285. MENG X, Kong X, Xia L, Wu R, et al
     The Role of Total-Body PET in Drug Development and Evaluation: Status and Outlook.
     J Nucl Med. 2024;65.
     PubMed     Abstract available
     
     
     
286. YANG W, Kang F, Chen Y, Zhu Z, et al
     Landscape of Nuclear Medicine in China and Its Progress on Theranostics.
     J Nucl Med. 2024;65.
     PubMed     Abstract available
     
     
     
287. AN S, Wang L, Xie F, Jiang D, et al
     Pathway to Approval of Innovative Radiopharmaceuticals in China.
     J Nucl Med. 2024;65.
     PubMed     Abstract available
     
     
     
288. CHEN H, Shi K, Cai W, Li S, et al
     Advancing Global Nuclear Medicine: The Role and Future Contributions of China.
     J Nucl Med. 2024;65.
     PubMed    
     
     
     
289. ZHAO L, Kang F, Pang Y, Fang J, et al
     Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China.
     J Nucl Med. 2024;65.
     PubMed     Abstract available
     
     
     
290. CHEN W, Li Y, Li Z, Jiang Y, et al
     Advantages and Challenges of Total-Body PET/CT at a Tertiary Cancer Center: Insights from Sun Yat-sen University Cancer Center.
     J Nucl Med. 2024;65.
     PubMed     Abstract available
     
     
     
291. KLINE B, Yadav S, Seo Y, Ippisch RC, et al
     (68)Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with (18)F-FDG.
     J Nucl Med. 2024 May 2:jnumed.123.267281. doi: 10.2967/jnumed.123.267281.
     PubMed     Abstract available
     
     
     
292. MA Y, Zeng J, Ding F, Xu Y, et al
     Cerebral (18)F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous System Toxicity After Immune Checkpoint Blockade Cancer Treatment.
     J Nucl Med. 2024 May 2:jnumed.123.267025. doi: 10.2967/jnumed.123.267025.
     PubMed     Abstract available
     
     
     
293. FEHER A, Bednarski B, Miller RJ, Shanbhag A, et al
     Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging.
     J Nucl Med. 2024;65:768-774.
     PubMed     Abstract available
     
     
     
294. 
     Gerald L. DeNardo, MD, 1932-2024.
     J Nucl Med. 2024;65:823.
     PubMed    
     
     
     April 2024
295. ROSEN J, Werner JM, Ceccon GS, Rosen EK, et al
     MRI and (18)F-FET PET for Multimodal Treatment Monitoring in Patients with Brain Metastases: A Cost-Effectiveness Analysis.
     J Nucl Med. 2024 Apr 25:jnumed.123.266687. doi: 10.2967/jnumed.123.266687.
     PubMed     Abstract available
     
     
     
296. NIKITAS J, Lam E, Booker KA, Fendler WP, et al
     Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
     J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004.
     PubMed     Abstract available
     
     
     
297. MINGELS C, Spencer BA, Nalbant H, Omidvari N, et al
     Dose Reduction in Pediatric Oncology Patients with Delayed Total-Body [(18)F]FDG PET/CT.
     J Nucl Med. 2024 Apr 25:jnumed.124.267521. doi: 10.2967/jnumed.124.267521.
     PubMed     Abstract available
     
     
     
298. DUAN H, Song H, Davidzon GA, Moradi F, et al
     Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
     J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017.
     PubMed     Abstract available
     
     
     
299. BURKETT BJ, Johnson DR, Lowe VJ
     Evaluation of Neurodegenerative Disorders with Amyloid-beta, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls.
     J Nucl Med. 2024 Apr 25:jnumed.123.266463. doi: 10.2967/jnumed.123.266463.
     PubMed     Abstract available
     
     
     
300. GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al
     RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234.
     PubMed     Abstract available
     
     
     
301. LEUBE J, Gustafsson J, Lassmann M, Salas-Ramirez M, et al
     A Deep-Learning-Based Partial-Volume Correction Method for Quantitative (177)Lu SPECT/CT Imaging.
     J Nucl Med. 2024 Apr 18:jnumed.123.266889. doi: 10.2967/jnumed.123.266889.
     PubMed     Abstract available
     
     
     
302. HAGENS MJ, van Leeuwen PJ, Wondergem M, Boellaard TN, et al
     A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers.
     J Nucl Med. 2024 Apr 18:jnumed.123.267260. doi: 10.2967/jnumed.123.267260.
     PubMed     Abstract available
     
     
     
303. MOSER R, Pfeiffer S, Cala L, Klein E, et al
     Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of (18)F-FDG PET/CT and Conventional CT Imaging.
     J Nucl Med. 2024 Apr 18:jnumed.123.266925. doi: 10.2967/jnumed.123.266925.
     PubMed     Abstract available
     
     
     
304. SWIHA M, Papa N, Sabahi Z, Ayati N, et al
     Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes.
     J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014.
     PubMed     Abstract available
     
     
     
305. QI C, Guo R, Chen Y, Li C, et al
     (68)Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients.
     J Nucl Med. 2024 Apr 11:jnumed.123.267110. doi: 10.2967/jnumed.123.267110.
     PubMed     Abstract available
     
     
     
306. ROHRICH M, Daum J, Gutjahr E, Spektor AM, et al
     Diagnostic Potential of Supplemental Static and Dynamic (68)Ga-FAPI-46 PET for Primary (18)F-FDG-Negative Pulmonary Lesions.
     J Nucl Med. 2024 Apr 11:jnumed.123.267103. doi: 10.2967/jnumed.123.267103.
     PubMed     Abstract available
     
     
     
307. O'DONNELL JL, Soda AK, Jiang H, Norris SA, et al
     PET Quantification of [(18)F]VAT in Human Brain and Its Test-Retest Reproducibility and Age Dependence.
     J Nucl Med. 2024 Apr 11:jnumed.123.266860. doi: 10.2967/jnumed.123.266860.
     PubMed     Abstract available
     
     
     
308. VISCUSE P, Devitt M, Dreicer R
     Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
     J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006.
     PubMed     Abstract available
     
     
     
309. WU Q, Gu F, O'Suilleabhain LD, Sari H, et al
     Mapping (18)F-FDG Kinetics Together with Patient-Specific Bootstrap Assessment of Uncertainties: An Illustration with Data from a PET/CT Scanner with a Long Axial Field of View.
     J Nucl Med. 2024 Apr 11:jnumed.123.266686. doi: 10.2967/jnumed.123.266686.
     PubMed     Abstract available
     
     
     
310. BARATTO L, Singh SB, Williams SE, Spunt SL, et al
     Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [(18)F]FDG PET/MRI: A Pilot Study.
     J Nucl Med. 2024 Apr 4:jnumed.123.266760. doi: 10.2967/jnumed.123.266760.
     PubMed     Abstract available
     
     
     
311. GEBHART G, Keyaerts M, Guiot T, Flamen P, et al
     Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
     J Nucl Med. 2024 Apr 4:jnumed.123.266384. doi: 10.2967/jnumed.123.266384.
     PubMed     Abstract available
     
     
     
312. BISCHOF GN, Brendel M, Barthel H, Theis H, et al
     Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [(18)F]PI-2620.
     J Nucl Med. 2024 Apr 4:jnumed.123.265930. doi: 10.2967/jnumed.123.265930.
     PubMed     Abstract available
     
     
     
313. RUWANPATHIRANA GP, Williams RC, Masters CL, Rowe CC, et al
     Impact of PET Reconstruction on Amyloid-beta Quantitation in Cross-Sectional and Longitudinal Analyses.
     J Nucl Med. 2024 Apr 4:jnumed.123.266188. doi: 10.2967/jnumed.123.266188.
     PubMed     Abstract available
     
     
     
314. SCHULER M, Hense J, Darwiche K, Michels S, et al
     Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
     J Nucl Med. 2024 Apr 4:jnumed.123.266979. doi: 10.2967/jnumed.123.266979.
     PubMed     Abstract available
     
     
     
315. LI Z, Benabdallah N, Luo J, Wahl RL, et al
     ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner-Collimator Configurations for (223)Ra-Based Radiopharmaceutical Therapies.
     J Nucl Med. 2024 Apr 4:jnumed.123.266719. doi: 10.2967/jnumed.123.266719.
     PubMed     Abstract available
     
     
     March 2024
316. ALTENA R, Buren SA, Blomgren A, Karlsson E, et al
     Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [(68)Ga]Ga-ABY-025: Results from a Pilot Study.
     J Nucl Med. 2024 Mar 28:jnumed.123.266847. doi: 10.2967/jnumed.123.266847.
     PubMed     Abstract available
     
     
     
317. COLLARINO A, Feudo V, Pasciuto T, Florit A, et al
     Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer?
     J Nucl Med. 2024 Mar 28:jnumed.123.267044. doi: 10.2967/jnumed.123.267044.
     PubMed     Abstract available
     
     
     
318. BLAKKISRUD J, Peterson AB, Wildermann SJ, Kingkiner G, et al
     SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [(177)Lu]Lu-DOTATATE.
     J Nucl Med. 2024 Mar 28:jnumed.123.266843. doi: 10.2967/jnumed.123.266843.
     PubMed     Abstract available
     
     
     
319. ZHANG X, Heo GS, Li A, Lahad D, et al
     Development of a CD163-Targeted PET Radiotracer That Images Resident Macrophages in Atherosclerosis.
     J Nucl Med. 2024 Mar 28:jnumed.123.266910. doi: 10.2967/jnumed.123.266910.
     PubMed     Abstract available
     
     
     
320. WANG Y, Abdelhafez YG, Spencer BA, Verma R, et al
     High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET.
     J Nucl Med. 2024 Mar 28:jnumed.123.267036. doi: 10.2967/jnumed.123.267036.
     PubMed     Abstract available
     
     
     
321. HAIDER SP, Zeevi T, Sharaf K, Gross M, et al
     Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.
     J Nucl Med. 2024 Mar 21:jnumed.123.266637. doi: 10.2967/jnumed.123.266637.
     PubMed     Abstract available
     
     
     
322. PRUIS IJ, Verburg FA, Balvers RK, Harteveld AA, et al
     [(18)F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors.
     J Nucl Med. 2024 Mar 21:jnumed.123.266853. doi: 10.2967/jnumed.123.266853.
     PubMed     Abstract available
     
     
     
323. LIU N, Yang X, Gao C, Wang J, et al
     Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses.
     J Nucl Med. 2024 Mar 21:jnumed.123.266888. doi: 10.2967/jnumed.123.266888.
     PubMed     Abstract available
     
     
     
324. JAGUST WJ, Mattay VS, Krainak DM, Wang SJ, et al
     Quantitative Brain Amyloid PET.
     J Nucl Med. 2024 Mar 21:jnumed.123.265766. doi: 10.2967/jnumed.123.265766.
     PubMed     Abstract available
     
     
     
325. CYTRYN SL, Pandit-Taskar N, Lumish MA, Maron SB, et al
     (18)F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer.
     J Nucl Med. 2024 Mar 21:jnumed.123.267186. doi: 10.2967/jnumed.123.267186.
     PubMed     Abstract available
     
     
     
326. SHI J, Li D, Chen M, Fu Y, et al
     The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study.
     J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
     PubMed     Abstract available
     
     
     
327. BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al
     Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions.
     J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075.
     PubMed     Abstract available
     
     
     
328. SAHIN E, Kus T, Aytekin A, Uzun E, et al
     (68)Ga-FAPI PET/CT as an Alternative to (18)F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma.
     J Nucl Med. 2024 Mar 14:jnumed.123.266798. doi: 10.2967/jnumed.123.266798.
     PubMed     Abstract available
     
     
     
329. PORTER JC, Ganeshan B, Win T, Fraioli F, et al
     [(18)F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases.
     J Nucl Med. 2024 Mar 14:jnumed.123.266445. doi: 10.2967/jnumed.123.266445.
     PubMed     Abstract available
     
     
     
330. PROVIDENCIA L, van der Weijden CWJ, Mohr P, van Sluis J, et al
     Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies?
     J Nucl Med. 2024 Mar 14:jnumed.123.266675. doi: 10.2967/jnumed.123.266675.
     PubMed     Abstract available
     
     
     
331. THOR M, Lee C, Sun L, Patel P, et al
     An (18)F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy.
     J Nucl Med. 2024 Mar 14:jnumed.123.266965. doi: 10.2967/jnumed.123.266965.
     PubMed     Abstract available
     
     
     
332. DRESCHER R, Greiser J, Grober S, Weisheit T, et al
     (64)Cu-DOTA Enables Late PET Imaging and Leak Detection in the Cerebrospinal Fluid Space.
     J Nucl Med. 2024 Mar 14:jnumed.123.267329. doi: 10.2967/jnumed.123.267329.
     PubMed    
     
     
     
333. HARTRAMPF PE, Huttmann T, Seitz AK, Kubler H, et al
     Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T.
     J Nucl Med. 2024 Mar 7:jnumed.123.266702. doi: 10.2967/jnumed.123.266702.
     PubMed     Abstract available
     
     
     
334. LI C, Chen Q, Tian Y, Chen J, et al
     (68)Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression.
     J Nucl Med. 2024 Mar 7:jnumed.123.266806. doi: 10.2967/jnumed.123.266806.
     PubMed     Abstract available
     
     
     
335. HOVHANNISYAN-BAGHDASARIAN N, Luporsi M, Captier N, Nioche C, et al
     Promising Candidate Prognostic Biomarkers in [(18)F]FDG PET Images: Evaluation in Independent Cohorts of Non-Small Cell Lung Cancer Patients.
     J Nucl Med. 2024 Mar 7:jnumed.123.266331. doi: 10.2967/jnumed.123.266331.
     PubMed     Abstract available
     
     
     
336. CUZZANI G, Fortunati E, Zanoni L, Nanni C, et al
     Case Report: Pulmonary Actinomyces Infection Mimics Lung Cancer on [(68)Ga]Ga-FAPI PET/CT.
     J Nucl Med. 2024 Mar 7:jnumed.123.267155. doi: 10.2967/jnumed.123.267155.
     PubMed    
     
     
     
337. FAROLFI A, Armstrong WR, Djaileb L, Gafita A, et al
     Differences and Common Ground in (177)Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
     J Nucl Med. 2024;65:438-445.
     PubMed     Abstract available
     
     
     February 2024
338. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
     Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
     J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
     PubMed     Abstract available
     
     
     
339. JIANG M, Tang S, Jenkins MD, Lee AC, et al
     Robust Quantification of Phosphodiesterase-4D in Monkey Brain with PET and (11)C-Labeled Radioligands That Avoid Radiometabolite Contamination.
     J Nucl Med. 2024 Feb 29:jnumed.123.266750. doi: 10.2967/jnumed.123.266750.
     PubMed     Abstract available
     
     
     
340. GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al
     First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189.
     PubMed    
     
     
     
341. BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al
     The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
     J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654.
     PubMed     Abstract available
     
     
     
342. EL FAKIRI M, Ayada N, Muller M, Hvass L, et al
     Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for Targeted alpha-Therapy of Prostate Cancer.
     J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043.
     PubMed     Abstract available
     
     
     
343. KOVACS DG, Ladefoged CN, Andersen KF, Brittain JM, et al
     Clinical Evaluation of Deep Learning for Tumor Delineation on (18)F-FDG PET/CT of Head and Neck Cancer.
     J Nucl Med. 2024 Feb 22:jnumed.123.266574. doi: 10.2967/jnumed.123.266574.
     PubMed     Abstract available
     
     
     
344. LI G, Ma W, Li X, Yang W, et al
     Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard.
     J Nucl Med. 2024 Feb 22:jnumed.123.265929. doi: 10.2967/jnumed.123.265929.
     PubMed     Abstract available
     
     
     
345. SLART RHJA, Bengel FM, Akincioglu C, Bourque JM, et al
     Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council.
     J Nucl Med. 2024 Feb 22:jnumed.123.266858. doi: 10.2967/jnumed.123.266858.
     PubMed     Abstract available
     
     
     
346. BOURBONNE V, Morjani M, Pradier O, Hatt M, et al
     PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non-Small Cell Lung Cancer Treated with Curative Radiotherapy.
     J Nucl Med. 2024 Feb 15:jnumed.123.266749. doi: 10.2967/jnumed.123.266749.
     PubMed     Abstract available
     
     
     
347. LOHMANN P, Gutsche R, Werner JM, Shah NJ, et al
     Example of Artificial Intelligence-Based Decision Support for Amino Acid PET: Early Prediction of Suspected Brain Tumor Foci for Patient Management.
     J Nucl Med. 2024 Feb 15:jnumed.123.267112. doi: 10.2967/jnumed.123.267112.
     PubMed    
     
     
     
348. DRAKE LR, Wu Y, Naganawa M, Asch R, et al
     First-in-Human Study of (18)F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding.
     J Nucl Med. 2024 Feb 15:jnumed.123.266470. doi: 10.2967/jnumed.123.266470.
     PubMed     Abstract available
     
     
     
349. LIU Z, Mhlanga JC, Xia H, Siegel BA, et al
     Need for Objective Task-Based Evaluation of Image Segmentation Algorithms for Quantitative PET: A Study with ACRIN 6668/RTOG 0235 Multicenter Clinical Trial Data.
     J Nucl Med. 2024 Feb 15:jnumed.123.266018. doi: 10.2967/jnumed.123.266018.
     PubMed     Abstract available
     
     
     
350. KISHAN AU, Siva S, Hofman MS, Nagarajah J, et al
     The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease.
     J Nucl Med. 2024 Feb 15:jnumed.123.266772. doi: 10.2967/jnumed.123.266772.
     PubMed     Abstract available
     
     
     
351. DUBASH S, Barwick TD, Kozlowski K, Rockall AG, et al
     Somatostatin Receptor Imaging with [(18)F]FET-betaAG-TOCA PET/CT and [(68)Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study.
     J Nucl Med. 2024 Feb 8:jnumed.123.266601. doi: 10.2967/jnumed.123.266601.
     PubMed     Abstract available
     
     
     
352. HIRMAS N, Hamacher R, Sraieb M, Kessler L, et al
     Diagnostic Accuracy of (68)Ga-FAPI Versus (18)F-FDG PET in Patients with Various Malignancies.
     J Nucl Med. 2024 Feb 8:jnumed.123.266652. doi: 10.2967/jnumed.123.266652.
     PubMed     Abstract available
     
     
     
353. GONDRY O, Caveliers V, Xavier C, Raes L, et al
     Phase II Trial Assessing the Repeatability and Tumor Uptake of [(68)Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.
     J Nucl Med. 2024;65:178-184.
     PubMed     Abstract available
     
     
     
354. OH M, Oh SJ, Lee SJ, Oh JS, et al
     One-Year Longitudinal Changes in Tau Accumulation on [(18)F]PI-2620 PET in the Alzheimer Spectrum.
     J Nucl Med. 2024 Feb 1:jnumed.123.265893. doi: 10.2967/jnumed.123.265893.
     PubMed     Abstract available
     
     
     
355. SOULEN MC, Rilling WS
     Clinical Outcomes After Personalized Dosimetry for (90)Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape.
     J Nucl Med. 2024;65:270-271.
     PubMed    
     
     
     
356. AL MANSOUR L, De Mestier L, Haissaguerre M, Afchain P, et al
     Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Networ
     J Nucl Med. 2024;65:258-263.
     PubMed     Abstract available
     
     
     
357. HAMACHER R, Pabst KM, Cheung PF, Heilig CE, et al
     Fibroblast Activation Protein alpha-Directed Imaging and Therapy of Solitary Fibrous Tumor.
     J Nucl Med. 2024;65:252-257.
     PubMed     Abstract available
     
     
     
358. WAGEMANS MEHM, Kunnen B, Stella M, van Rooij R, et al
     Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma.
     J Nucl Med. 2024;65:272-278.
     PubMed     Abstract available
     
     
     
359. HE Y, Kramer SD, Grether U, Wittwer MB, et al
     Identification of (R)-[(18)F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development.
     J Nucl Med. 2024;65:300-305.
     PubMed     Abstract available
     
     
     
360. MILEVA M, Marin G, Levillain H, Artigas C, et al
     Prediction of (177)Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.
     J Nucl Med. 2024;65:236-244.
     PubMed     Abstract available
     
     
     
361. GIRUM KB, Cottereau AS, Vercellino L, Rebaud L, et al
     Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
     J Nucl Med. 2024;65:313-319.
     PubMed     Abstract available
     
     
     
362. CHIESA C, Bagnalasta M, Maccauro M
     Good Voxel Dosimetry with a Simplified Study Design Resulted in Improvable Safety Limits.
     J Nucl Med. 2024;65:331-332.
     PubMed    
     
     
     January 2024
363. GU B, Yang Z, Du X, Xu X, et al
     Imaging of Tumor Stroma Using (68)Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial.
     J Nucl Med. 2024 Jan 25:jnumed.123.266556. doi: 10.2967/jnumed.123.266556.
     PubMed     Abstract available
     
     
     
364. KIRBY A, Graf D, Suchy M, Calvert ND, et al
     It's a Trap! Aldolase-Prescribed C(4) Deoxyradiofluorination Affords Intracellular Trapping and the Tracing of Fructose Metabolism by PET.
     J Nucl Med. 2024 Jan 25:jnumed.123.266905. doi: 10.2967/jnumed.123.266905.
     PubMed     Abstract available
     
     
     
365. YEH R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al
     First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
     J Nucl Med. 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392.
     PubMed     Abstract available
     
     
     
366. BUCHERT R, Szabo B, Kovacs A, Buddenkotte T, et al
     Dopamine Transporter SPECT with 12-Minute Scan Duration Using Multiple-Pinhole Collimators.
     J Nucl Med. 2024 Jan 18:jnumed.123.266276. doi: 10.2967/jnumed.123.266276.
     PubMed     Abstract available
     
     
     
367. LIGHT A, Lazic S, Houghton K, Bayne M, et al
     Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
     J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527.
     PubMed     Abstract available
     
     
     
368. BARLATEY SL, Mignardot CG, Friedrichs-Maeder C, Schindler K, et al
     Triggered Seizures for Ictal SPECT Imaging: A Case Series and Feasibility Study.
     J Nucl Med. 2024 Jan 11:jnumed.123.266515. doi: 10.2967/jnumed.123.266515.
     PubMed     Abstract available
     
     
     
369. KOSHKIN VS, Kumar V, Kline B, Escobar D, et al
     Initial Experience with (68)Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
     J Nucl Med. 2024 Jan 11:jnumed.123.266390. doi: 10.2967/jnumed.123.266390.
     PubMed     Abstract available
     
     
     
370. UNTERRAINER LM, Memarzadeh S, Moatamed NA, Benz MR, et al
     [(68)Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor.
     J Nucl Med. 2024 Jan 11:jnumed.123.266732. doi: 10.2967/jnumed.123.266732.
     PubMed    
     
     
     
371. HOPE TA, Jadvar H
     PSMA PET AUC Updates: Inclusion of rh-PSMA-7.3.
     J Nucl Med. 2024 Jan 4:jnumed.123.267042. doi: 10.2967/jnumed.123.267042.
     PubMed    
     
     
     
372. UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al
     PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
     J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.
     PubMed    
     
     
     
373. DE WINTER RW, van Diemen PA, Schumacher SP, Jukema RA, et al
     Hemodynamic Insights into Combined Fractional Flow Reserve and Instantaneous Wave-Free Ratio Assessment Through Quantitative [(15)O]H(2)O PET Myocardial Perfusion Imaging.
     J Nucl Med. 2024 Jan 4:jnumed.123.265973. doi: 10.2967/jnumed.123.265973.
     PubMed     Abstract available
     
     
     
374. RAHBAR K, Boegemann M
     The Imperative for Comparative Studies in Nuclear Medicine: Elevating (177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
     J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952.
     PubMed    
     
     
     
375. LI X, Lu N, Lin L, Chen Y, et al
     (18)F-FAPI-04 Outperforms (18)F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma.
     J Nucl Med. 2024 Jan 4:jnumed.123.266283. doi: 10.2967/jnumed.123.266283.
     PubMed     Abstract available
     
     
     
376. ZHAO L, Pang Y, Fang J, Chen J, et al
     Design, Preclinical Evaluation, and Clinical Translation of (68)Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.
     J Nucl Med. 2024 Jan 4:jnumed.123.266183. doi: 10.2967/jnumed.123.266183.
     PubMed     Abstract available
     
     
     
377. STRUNK M, Heo GS, Hess A, Luehmann H, et al
     Toward Quantitative Multisite Preclinical Imaging Studies in Acute Myocardial Infarction: Evaluation of the Immune-Fibrosis Axis.
     J Nucl Med. 2024 Jan 4:jnumed.123.266526. doi: 10.2967/jnumed.123.266526.
     PubMed     Abstract available
     
     
     
378. SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al
     Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
     J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495.
     PubMed     Abstract available
     
     
     
379. SPEKTOR AM, Gutjahr E, Lang M, Glatting FM, et al
     Immunohistochemical FAP Expression Reflects (68)Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma.
     J Nucl Med. 2024;65:52-58.
     PubMed     Abstract available
     
     
     
380. PAPPAS V, Czernin J
     Expanding the Mission and Influence of SNMMI: A Conversation Between Johannes Czernin and Virginia Pappas About Her Career in SNMMI Leadership.
     J Nucl Med. 2024;65:1-3.
     PubMed    
     
     
     
381. POPLAWSKI SE, Hallett RM, Dornan MH, Novakowski KE, et al
     Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-alpha (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
     J Nucl Med. 2024;65:100-108.
     PubMed     Abstract available
     
     
     
382. MALIHA PG, Hotta M, Czernin J, Calais J, et al
     Characterizing Normal Variant [(68)Ga]Ga-FAPI-46 Uptake in the Epididymis.
     J Nucl Med. 2024;65:59-62.
     PubMed     Abstract available
     
     
     
383. LUTHRIA G, Baratto L, Adams L, Morakote W, et al
     Increased Metabolic Activity of the Thymus and Lymph Nodes in Pediatric Oncology Patients After Coronavirus Disease 2019 Vaccination.
     J Nucl Med. 2024;65:22-24.
     PubMed     Abstract available
     
     
     
384. ENKE JS, Reitsam NG, Grosser B, Kircher M, et al
     C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy of Multiple Myeloma Using [(99m)Tc]Tc-PentixaTec.
     J Nucl Med. 2024;65:163-164.
     PubMed    
     
     
     December 2023
385. CHAN DL, Hayes AR, Karfis I, Conner A, et al
     [(18)F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study.
     J Nucl Med. 2023 Dec 21:jnumed.123.266346. doi: 10.2967/jnumed.123.266346.
     PubMed     Abstract available
     
     
     
386. MIAO Y, Feng R, Yu T, Guo R, et al
     Value of (68)Ga-FAPI-04 and (18)F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
     J Nucl Med. 2023 Dec 21:jnumed.123.266403. doi: 10.2967/jnumed.123.266403.
     PubMed     Abstract available
     
     
     
387. VENTURA D, Dittmann M, Buther F, Schafers M, et al
     Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity [(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma.
     J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513.
     PubMed     Abstract available
     
     
     
388. DIERKS A, Gable A, Rinscheid A, Wienand G, et al
     First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.
     J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741.
     PubMed     Abstract available
     
     
     
389. BARTLETT EA, Lesanpezeshki M, Anishchenko S, Shkolnik I, et al
     Dynamic Human Brain Imaging with a Portable PET Camera: Comparison to a Standard Scanner.
     J Nucl Med. 2023 Dec 14:jnumed.122.265309. doi: 10.2967/jnumed.122.265309.
     PubMed     Abstract available
     
     
     
390. FETTAHOGLU A, Zhao M, Khalighi M, Vossler H, et al
     Early-Frame [(18)F]Florbetaben PET/MRI for Cerebral Blood Flow Quantification in Patients with Cognitive Impairment: Comparison to an [(15)O]Water Gold Standard.
     J Nucl Med. 2023 Dec 7:jnumed.123.266273. doi: 10.2967/jnumed.123.266273.
     PubMed     Abstract available
     
     
     
391. MANKOFF D, Balogova S, Dunnwald L, Dehdashti F, et al
     Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16alpha-[(18)F]Fluoro-17beta-Estradiol PET.
     J Nucl Med. 2023 Dec 7:jnumed.123.266938. doi: 10.2967/jnumed.123.266938.
     PubMed     Abstract available
     
     
     
392. NADEL HR
     A Strategic Approach to Advancing Nuclear Medicine and Molecular Imaging.
     J Nucl Med. 2023;64:1843-1844.
     PubMed    
     
     
     
393. BLAZHENETS G, Soleimani-Meigooni DN, Thomas W, Mundada N, et al
     [(18)F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration.
     J Nucl Med. 2023;64:1980-1989.
     PubMed     Abstract available
     
     
     
394. FANI M, Nicolas GP
     (61)Cu-Labeled Radiotracers: Alternative or Choice?
     J Nucl Med. 2023;64:1855-1857.
     PubMed    
     
     
     November 2023
395. EMMETT L, Papa N, Counter W, Calais J, et al
     Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
     J Nucl Med. 2023 Nov 30:jnumed.123.266164. doi: 10.2967/jnumed.123.266164.
     PubMed     Abstract available
     
     
     
396. WANG F, Liu C, Vidal I, Mana-Ay M, et al
     Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET/CT.
     J Nucl Med. 2023 Nov 30:jnumed.123.266005. doi: 10.2967/jnumed.123.266005.
     PubMed     Abstract available
     
     
     
397. DING J, Li X, Liu S, Gao Y, et al
     Clinical Value of (68)Ga-Pentixafor PET/CT in Subtype Diagnosis of Primary Aldosteronism Patients with Adrenal Micronodules.
     J Nucl Med. 2023 Nov 30:jnumed.123.266061. doi: 10.2967/jnumed.123.266061.
     PubMed     Abstract available
     
     
     
398. KLUGE K, Einspieler H, Haberl D, Spielvogel C, et al
     Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [(68)Ga]Ga-PSMA-11 PET/CT Study.
     J Nucl Med. 2023 Nov 30:jnumed.123.266158. doi: 10.2967/jnumed.123.266158.
     PubMed     Abstract available
     
     
     
399. PUUVUORI E, Shen Y, Hulsart-Billstrom G, Mitran B, et al
     Noninvasive PET Detection of CD69-Positive Immune Cells Before Signs of Clinical Disease in Inflammatory Arthritis.
     J Nucl Med. 2023 Nov 30:jnumed.123.266336. doi: 10.2967/jnumed.123.266336.
     PubMed     Abstract available
     
     
     
400. NDLOVU H, Lawal I, Mokoala K, Disenyane D, et al
     Imaging PARP Upregulation with [(123)I]I-PARPi SPECT/CT in Small Cell Neuroendocrine Carcinoma.
     J Nucl Med. 2023 Nov 30:jnumed.123.266348. doi: 10.2967/jnumed.123.266348.
     PubMed    
     
     
     
401. DOERING E, Antonopoulos G, Hoenig M, van Eimeren T, et al
     MRI or (18)F-FDG PET for Brain Age Gap Estimation: Links to Cognition, Pathology, and Alzheimer Disease Progression.
     J Nucl Med. 2023 Nov 30:jnumed.123.265931. doi: 10.2967/jnumed.123.265931.
     PubMed     Abstract available
     
     
     
402. KURONUMA K, Wei CC, Singh A, Lemley M, et al
     Automated Motion Correction for Myocardial Blood Flow Measurements and Diagnostic Performance of (82)Rb PET Myocardial Perfusion Imaging.
     J Nucl Med. 2023 Nov 30:jnumed.123.266208. doi: 10.2967/jnumed.123.266208.
     PubMed     Abstract available
     
     
     
403. QUAN Z, Han Z, Yang Y, Wang J, et al
     Noninvasive Monitoring of Immunotherapy in Lung Cancer by Lymphocyte Activation Gene 3 PET Imaging of Tumor-Infiltrating Lymphocytes.
     J Nucl Med. 2023 Nov 16:jnumed.123.266002. doi: 10.2967/jnumed.123.266002.
     PubMed     Abstract available
     
     
     
404. KESSLER L, Hirmas N, Pabst KM, Hamacher R, et al
     (68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial.
     J Nucl Med. 2023 Nov 16:jnumed.122.264827. doi: 10.2967/jnumed.122.264827.
     PubMed     Abstract available
     
     
     
405. NAMMAS W, Paunonen C, Teuho J, Siekkinen R, et al
     Imaging of Myocardial alpha(v)beta(3) Integrin Expression for Evaluation of Myocardial Injury After Acute Myocardial Infarction.
     J Nucl Med. 2023 Nov 16:jnumed.123.266148. doi: 10.2967/jnumed.123.266148.
     PubMed     Abstract available
     
     
     
406. BALAJI V, Song TA, Malekzadeh M, Heidari P, et al
     Artificial Intelligence for PET and SPECT Image Enhancement.
     J Nucl Med. 2023 Nov 9:jnumed.122.265000. doi: 10.2967/jnumed.122.265000.
     PubMed     Abstract available
     
     
     
407. GUNTHER T, Holzleitner N, Viering O, Beck R, et al
     Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
     J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537.
     PubMed     Abstract available
     
     
     
408. CARLIER T, Frecon G, Mateus D, Rizkallah M, et al
     Prognostic Value of (18)F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study.
     J Nucl Med. 2023 Nov 9:jnumed.123.265872. doi: 10.2967/jnumed.123.265872.
     PubMed     Abstract available
     
     
     
409. CHEN L, Zheng S, Chen L, Xu S, et al
     (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.
     J Nucl Med. 2023 Nov 2:jnumed.123.266079. doi: 10.2967/jnumed.123.266079.
     PubMed     Abstract available
     
     
     
410. REZAZADEH F, Kilcline AP, Viola NT
     Imaging Agents for PET of Inflammatory Bowel Disease: A Review.
     J Nucl Med. 2023 Nov 2:jnumed.123.265935. doi: 10.2967/jnumed.123.265935.
     PubMed     Abstract available
     
     
     
411. VIERING O, Gunther T, Holzleitner N, Dierks A, et al
     CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [(68)Ga]Ga-DOTA-CCK-66.
     J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380.
     PubMed    
     
     
     
412. GEBHART G
     (18)F-FDG PET "Metabolic Response" to Neoadjuvant Systemic Therapy for Breast Cancer: Quo Vadis?
     J Nucl Med. 2023;64:1697-1698.
     PubMed    
     
     
     
413. KNUUTI J, Tuisku J, Karpijoki H, Iida H, et al
     Quantitative Perfusion Imaging with Total-Body PET.
     J Nucl Med. 2023;64.
     PubMed     Abstract available
     
     
     
414. DI CARLI MF
     Future of Radionuclide Myocardial Perfusion Imaging: Transitioning from SPECT to PET.
     J Nucl Med. 2023;64.
     PubMed    
     
     
     
415. BENGEL FM, Di Carli MF
     The Evolution of Cardiac Nuclear Imaging.
     J Nucl Med. 2023;64.
     PubMed    
     
     
     
416. ROLL W, Faust A, Hermann S, Schafers M, et al
     Infection Imaging: Focus on New Tracers?
     J Nucl Med. 2023;64.
     PubMed     Abstract available
     
     
     
417. LI EJ, Lopez JE, Spencer BA, Abdelhafez Y, et al
     Total-Body Perfusion Imaging with [(11)C]-Butanol.
     J Nucl Med. 2023;64:1831-1838.
     PubMed     Abstract available
     
     
     October 2023
418. KAYAL G, Barbosa N, Calderon Marin C, Ferrer L, et al
     Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study.
     J Nucl Med. 2023 Oct 26:jnumed.122.265340. doi: 10.2967/jnumed.122.265340.
     PubMed     Abstract available
     
     
     
419. MAULER J, Lohmann P, Maudsley AA, Sheriff S, et al
     Diagnostic Accuracy of MR Spectroscopic Imaging and (18)F-FET PET for Identifying Glioma: A Biopsy-Controlled Hybrid PET/MRI Study.
     J Nucl Med. 2023 Oct 26:jnumed.123.265868. doi: 10.2967/jnumed.123.265868.
     PubMed     Abstract available
     
     
     
420. XU W, Cai J, Peng T, Meng T, et al
     Fibroblast Activation Protein-Targeted PET/CT with (18)F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with (18)F-FDG PET/CT.
     J Nucl Med. 2023 Oct 26:jnumed.123.266329. doi: 10.2967/jnumed.123.266329.
     PubMed     Abstract available
     
     
     
421. LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al
     Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
     J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044.
     PubMed     Abstract available
     
     
     
422. KAIREMO K, Czernin J
     Advancing Nuclear Medicine at the Multiomics Intersection: Johannes Czernin Discusses Innovation and Translation with Kalevi Kairemo.
     J Nucl Med. 2023 Oct 19:jnumed.123.266793. doi: 10.2967/jnumed.123.266793.
     PubMed    
     
     
     
423. YAMAGISHI S, Miwa K, Kamitaki S, Anraku K, et al
     Performance Characteristics of a New-Generation Digital Bismuth Germanium Oxide PET/CT System, Omni Legend 32, According to NEMA NU 2-2018 Standards.
     J Nucl Med. 2023 Oct 19:jnumed.123.266140. doi: 10.2967/jnumed.123.266140.
     PubMed     Abstract available
     
     
     
424. LI X, Ye J, Wang J, Quan Z, et al
     First-in-Humans PET Imaging of KRAS(G12C) Mutation Status in Non-Small Cell Lung and Colorectal Cancer Patients Using [(18)F]PFPMD.
     J Nucl Med. 2023 Oct 12:jnumed.123.265715. doi: 10.2967/jnumed.123.265715.
     PubMed     Abstract available
     
     
     
425. WATABE T, Kabayama K, Naka S, Yamamoto R, et al
     Immuno-PET and Targeted alpha-Therapy Using Anti-Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.
     J Nucl Med. 2023 Oct 12:jnumed.123.266313. doi: 10.2967/jnumed.123.266313.
     PubMed     Abstract available
     
     
     
426. AL-TOUBAH T, Montilla-Soler J, El-Haddad G, Haider M, et al
     Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.
     J Nucl Med. 2023 Oct 5:jnumed.123.266185. doi: 10.2967/jnumed.123.266185.
     PubMed     Abstract available
     
     
     
427. DUELL J, Buck AK, Hartrampf PE, Schlotelburg W, et al
     Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.
     J Nucl Med. 2023 Oct 5:jnumed.123.266074. doi: 10.2967/jnumed.123.266074.
     PubMed     Abstract available
     
     
     
428. SCHEUERMANN JS, Pryma DA
     Choosing the Right Metrics for Evaluation of Radiopharmaceutical Therapy Dosimetry Methodologies.
     J Nucl Med. 2023;64:1617-1618.
     PubMed    
     
     
     
429. CHICHEPORTICHE A, Sason M, Zidan M, Godefroy J, et al
     Impact of Single-Time-Point Estimates of (177)Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles.
     J Nucl Med. 2023;64:1610-1616.
     PubMed     Abstract available
     
     
     
430. GANZ PA, Czernin J
     Pioneering Research on Cancer Quality of Life and Outcomes: Johannes Czernin Discusses a Half-Century of Whole-Patient Focus with Patricia A. Ganz.
     J Nucl Med. 2023;64:1506-1508.
     PubMed    
     
     
     
431. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
     Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
     J Nucl Med. 2023;64:1632-1637.
     PubMed     Abstract available
     
     
     
432. KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al
     Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
     J Nucl Med. 2023;64:1654-1659.
     PubMed     Abstract available
     
     
     
433. COOK BE, Nag S, Arakawa R, Lin EY, et al
     Development of a PET Tracer for OGA with Improved Kinetics in the Living Brain.
     J Nucl Med. 2023;64:1588-1593.
     PubMed     Abstract available
     
     
     
434. HERINGTON J, McCradden MD, Creel K, Boellaard R, et al
     Ethical Considerations for Artificial Intelligence in Medical Imaging: Deployment and Governance.
     J Nucl Med. 2023;64:1509-1515.
     PubMed     Abstract available
     
     
     September 2023
435. SHAGERA QA, Karfis I, Kristanto P, Spyridon S, et al
     PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
     J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874.
     PubMed     Abstract available
     
     
     
436. HABERBOSCH L, Gillett D, MacFarlane J, Koulouri O, et al
     Dual Role for l-[Methyl-(11)C]-Methionine PET in Acromegaly: Confirming Remission and Detecting Recurrence.
     J Nucl Med. 2023 Sep 28:jnumed.123.266446. doi: 10.2967/jnumed.123.266446.
     PubMed    
     
     
     
437. CONSTANTINESCU CC, Brown T, Wang S, Yin W, et al
     Clinical Characterization of [(18)F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy.
     J Nucl Med. 2023 Sep 28:jnumed.123.265912. doi: 10.2967/jnumed.123.265912.
     PubMed     Abstract available
     
     
     
438. ALBERTO S, Ordonez AA, Arjun C, Aulakh GK, et al
     The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection.
     J Nucl Med. 2023 Sep 28:jnumed.123.265906. doi: 10.2967/jnumed.123.265906.
     PubMed     Abstract available
     
     
     
439. CHAN CY, Chen Z, Guibbal F, Dias G, et al
     [(123)I]CC1: A PARP-Targeting, Auger Electron-Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer.
     J Nucl Med. 2023 Sep 28:jnumed.123.265429. doi: 10.2967/jnumed.123.265429.
     PubMed     Abstract available
     
     
     
440. SCHMIDKONZ C, Atzinger A, Ramming A, Kuwert T, et al
     FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic Disorders.
     J Nucl Med. 2023 Sep 21:jnumed.123.266182. doi: 10.2967/jnumed.123.266182.
     PubMed    
     
     
     
441. KLUGE K, Haberl D, Einspieler H, Rasul S, et al
     Antihormonal-Treatment Status Affects (68)Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.
     J Nucl Med. 2023 Sep 21:jnumed.123.265980. doi: 10.2967/jnumed.123.265980.
     PubMed     Abstract available
     
     
     
442. ITTI E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, et al
     Validation of the DeltaSUV(max) for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.
     J Nucl Med. 2023 Sep 21:jnumed.123.265871. doi: 10.2967/jnumed.123.265871.
     PubMed     Abstract available
     
     
     
443. DEMMERT TT, Pomykala KL, Lanzafame H, Pabst KM, et al
     Oncologic Staging with (68)Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than (18)F-FDG PET/CT.
     J Nucl Med. 2023 Sep 21:jnumed.123.265751. doi: 10.2967/jnumed.123.265751.
     PubMed     Abstract available
     
     
     
444. ROGASCH JMM, Metzger G, Preisler M, Galler M, et al
     ChatGPT: Can You Prepare My Patients for [(18)F]FDG PET/CT and Explain My Reports?
     J Nucl Med. 2023 Sep 14:jnumed.123.266114. doi: 10.2967/jnumed.123.266114.
     PubMed     Abstract available
     
     
     
445. ALTENA R, Af Buren S, Tran T, Axelsson R, et al
     HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
     J Nucl Med. 2023 Sep 14:jnumed.123.266101. doi: 10.2967/jnumed.123.266101.
     PubMed    
     
     
     
446. SEBAN RD
     Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
     J Nucl Med. 2023 Sep 14:jnumed.123.266490. doi: 10.2967/jnumed.123.266490.
     PubMed    
     
     
     
447. GEORGOULIAS P, Angelidis G, Koukouraki S, Koutsikos J, et al
     Debating the Future of Nuclear Medicine: The Greek Experience.
     J Nucl Med. 2023 Sep 14:jnumed.123.266646. doi: 10.2967/jnumed.123.266646.
     PubMed    
     
     
     
448. GOGOLA A, Lopresti BJ, Tudorascu D, Snitz B, et al
     Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies.
     J Nucl Med. 2023 Sep 14:jnumed.123.265941. doi: 10.2967/jnumed.123.265941.
     PubMed    
     
     
     
449. KOERBER SA, Rohrich M, Walkenbach L, Liermann J, et al
     Impact of (68)Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.
     J Nucl Med. 2023 Sep 7:jnumed.123.266046. doi: 10.2967/jnumed.123.266046.
     PubMed     Abstract available
     
     
     
450. MURTHY V, Gafita A, Thin P, Nguyen K, et al
     Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with (177)Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
     J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155.
     PubMed     Abstract available
     
     
     
451. SUNDERLAND JJ, Graves SA, York DM, Mundt CA, et al
     Response to "Critique and Discussion of 'Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose'".
     J Nucl Med. 2023 Sep 7:jnumed.123.266596. doi: 10.2967/jnumed.123.266596.
     PubMed    
     
     
     
452. KARIMZADEH A, Soeiro P, Feuerecker B, Hecker CS, et al
     Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of (177)Lu-PSMA I&T.
     J Nucl Med. 2023 Sep 7:jnumed.123.265878. doi: 10.2967/jnumed.123.265878.
     PubMed     Abstract available
     
     
     
453. MANKOFF D
     The Future of Nuclear Medicine.
     J Nucl Med. 2023;64:1329-1330.
     PubMed    
     
     
     
454. KRAEBER-BODERE F, Jamet B, Bezzi D, Zamagni E, et al
     New Developments in Myeloma Treatment and Response Assessment.
     J Nucl Med. 2023;64:1331-1343.
     PubMed     Abstract available
     
     
     
455. WANG C, Peterson AB, Wong KK, Roseland ME, et al
     Single-Time-Point Imaging for Dosimetry After [(177)Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection.
     J Nucl Med. 2023;64:1463-1470.
     PubMed     Abstract available
     
     
     
456. HARTLAPP I, Hartrampf PE, Serfling SE, Wild V, et al
     CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.
     J Nucl Med. 2023;64:1424-1430.
     PubMed     Abstract available
     
     
     
457. PANG Y, Zhao L, Fang J, Chen J, et al
     Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
     J Nucl Med. 2023;64:1449-1455.
     PubMed     Abstract available
     
     
     
458. AHMAD AA, Ghim M, Toczek J, Neishabouri A, et al
     Multimodality Imaging of Aortic Valve Calcification and Function in a Murine Model of Calcific Aortic Valve Disease and Bicuspid Aortic Valve.
     J Nucl Med. 2023;64:1487-1494.
     PubMed     Abstract available
     
     
     August 2023
459. ALAN-SELCUK N, Beydagi G, Demirci E, Ocak M, et al
     Clinical Experience with [(225)Ac]Ac-PSMA Treatment in Patients with [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2023 Aug 24:jnumed.123.265546. doi: 10.2967/jnumed.123.265546.
     PubMed     Abstract available
     
     
     
460. EIFER M, Alipour R, Hofman MS, Ravi Kumar AS, et al
     Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?
     J Nucl Med. 2023 Aug 17:jnumed.123.266025. doi: 10.2967/jnumed.123.266025.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Nuclear Medicine is free of charge.